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CHAPTER 1. Multimetallic Lanthanide Complexes Toward Imaging Applications
Adapted with permission from Moore, J.D.; Allen, M.J. Recent Patents on Nanomedicine 2011,
1, 88–100. Copyright 2011 Bentham Science Publishers.
Introduction
Multimetallic lanthanide (Ln3+) complexes are widely studied because of their magnetic
and luminescent properties. Due to these properties, multilanthanide complexes are potentially
useful in nanomedicine, provided the complexes are chemically and kinetically inert, non-toxic,
monodisperse, and well characterized. While many multimetallic lanthanide complexes have
been studied, few meet all of these requirements.1–4 The focus of this chapter is discrete
multilanthanide complexes reported during the last five years that exhibit covalently linked
chelates known to bind lanthanide ions tightly (log KGdL > 18). Generally, this category of
coordination compounds falls in an intermediate molecular weight range (1–6 kDa) and exhibits
relatively short metal–metal distances (<600 nm). Characterization of these discrete complexes
allows for structure–function relationships to be definitively analyzed, and these relationships are
important for understanding and optimizing similar and larger systems including polymers and
dendrimers.5–21 The scope of lanthanide-containing materials is too vast to be adequately
described in a single chapter; consequently, this chapter will not address dendrimeric, polymeric,
or bioconjugated polylanthanide complexes. Reviews for these types of molecules are available
elsewhere.1,4,22–27
A unique feature of the lanthanides is that the most stable oxidation state for all of these
elements is +3, yet they display a wide range of magnetic and luminescent properties over a
relatively narrow size range (the +3 ionic radii of elements 58–71 are in the range of 102–86
pm).28 A consequence of these properties is that lanthanide ions tend to form nearly isostructural
complexes that commonly exhibit coordination numbers of 8–10. From a synthetic perspective,
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the near-isostructural nature of lanthanides is advantageous because a single ligand can be used
to generate lanthanide complexes for a variety of medical applications including magnetic
resonance imaging (MRI), optical imaging, and immunogenic assays. With such a wide variety
of properties incorporated into almost isostructural elements a single ligand can generate a
variety of complexes, accessing a host of different properties. Therefore, ligand design is a key
focus for researchers interested in exploring applications of these elements.
Two applications for which multilanthanide complexes are studied include contrast
agents for MRI and luminescent imaging probes. This chapter will cover these two topics with a
brief introduction to each topic preceding a detailed discussion of the ligand design and
multilanthanide complexes that have been investigated for each application. Chapter 1 will
conclude with a summary of the contributions made to each field, the current state of
multilanthanide research, a discussion of the future potential for this class of complexes, a
description of how this work influenced the goals of my research, and a summary of the
remaining chapters of my thesis.
Multimeric Ligand Design
A variety of ligand motifs have been used to form multimetallic lanthanide complexes for
medical applications. Discussion of the specific syntheses of multimeric ligands is beyond the
scope of this article. The techniques employed have been developed in monomeric ligand
syntheses that are thoroughly reviewed elsewhere.29 As a result of the extensive research of
monomeric polyamino polycarboxylates, the majority of multimeric ligands are derivatives of
the

monomeric

chelators

diethylenetriaminepentaacetic

acid

(DTPA)

and

1,4,7,10-

tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) (Figure 1.1). Both DOTA and DTPA
form kinetically inert complexes with lanthanides under physiological conditions (kd = 1.2 × 103

3
and

21

s–1

for

GdDTPA

and

GdDOTA,
O

OH

respectively), and the gadolinium complexes of
these ligands are clinically approved contrast
agents for MRI.2,3 While this review is not focused

O

HO

N

N

N

N
HO

chemistry of these complexes strongly influences
the

design

of

ligands

for

multilanthanide

complexes. Thus, a brief discussion of the

N

N

O

N

OH
O

O

DOTA

on monometallic lanthanide complexes, the basic

O
OH

OH
OH
O

OH

HO

O

O

DTPA

Figure 1.1. Molecular structures of
macrocyclic DOTA and acyclic DTPA.
Reprinted with permission from Moore,
J.D.; Allen, M.J. Recent Patents on
Nanomedicine 2011, 1, 88–100.
Copyright 2011 Bentham Science
Publishers.

properties of monomeric complexes will be useful in understanding the design of their
multimeric analogs.
Most kinetically inert lanthanide complexes contain polydentate chelates with nitrogenand oxygen-based donors.2,3 The majority of these ligands are octadentate, leaving one
coordination site for a solvent molecule or other ligand to bind to the metal ion. Two factors
contribute to the inertness of these complexes: (1) the chelate effect and (2) electrostatic
attraction. Furthermore, macrocyclic-based ligands such as DOTA gain additional stability over
their acyclic counterparts due to the macrocyclic effect. Consequently, many multimeric ligands
feature macrocyclic chelates, and a common scaffold for these chelates is 1,4,7,10tetraazacyclododecane (cyclen).
Due to the success of GdDOTA as a contrast agent for MRI, N-functionalized-cyclenbased chelates are common in multilanthanide complexes. Cyclen has been functionalized with a
variety of substituents including acetates, amides, phosphonates, alcohols, and ketones.30–33 Due
to the difference in basicity and nucleophilicity of its four nitrogen atoms, cyclen can be
selectively functionalized such that one, two, or three nitrogens remain available for substitution
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after one substituent is attached.29 Thus, ligands can be designed in which three substituents
serve as donors to the metal center while the remaining substituent covalently links multiple
chelating moieties together (for example DO3A, Figure 1.2). The linking substituent is often
designed with a donor atom such that eight donors are maintained and the kinetic stability of the
chelate is minimally compromised.3 This popular strategy was demonstrated in early contrast
agent research by Tweedle and coworkers with the DO3A synthon.34
Although macrocyclic chelates are the most popular motifs used in multilanthanide
complexes, acyclic chelates offer a different set of structural variations. A common acyclic
chelate motif is diethylenetriaminetetraacetic acid (DTTA) (Figure 1.2). Multimeric ligands
featuring this motif sometimes require sequential protection and deprotection steps to attach a
linking moiety selectively.35 The kinetic
HO

stability of the resulting lanthanide complexes

N

is reduced relative to the parent DTPA
complex when the linking moiety does not

N

35

only seven metal-binding sites.

The reduced

stability of seven-coordinate acyclic chelates
has limited their use in multilanthanide

O
OH

N

N
O

O

OH

DO3A

contain a donor atom, leaving the chelate with

O

O

N
N

N

HO

OH
OH

HO

O

O

DTTA

Figure 1.2. Common chelates in multimeric
ligands. Arrows point to positions where
linking substituents can be attached.
Reprinted with permission from Moore,
J.D.; Allen, M.J. Recent Patents on
Nanomedicine 2011, 1, 88–100. Copyright
2011 Bentham Science Publishers.

complexes.
Of equal importance to chelate design is the choice of linking moieties to provide
functionality. Linkers are used to determine the number of chelates, control metal–metal
distance, rigidify the relative motion of metal ions, interact with analytes, and function as
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antennas for absorbance and energy transfer. Linker structure and function will be discussed in
detail in the following sections.
Contrast Agents for MRI
The first application of multilanthanide systems that this chapter will describe is contrast
agents for MRI, which is an important diagnostic technique for the medical field. Roughly 30%
of images acquired in a clinical setting involve the administration of a contrast agent to increase
the diagnostic information available from the images.2 Contrast agents are paramagnetic
substances that decrease the longitudinal (T1) and transverse (T2) relaxation times of water
protons, thereby increasing contrast in images. Detailed reviews of relaxation theory have been
published.3,36,37 With seven unpaired electrons, Gd3+ is highly paramagnetic and especially well
suited for use as a T1-shortening contrast agent for MRI. However, Gd3+ is toxic as the free ion
and, therefore, must be chelated in a kinetically inert ligand for use in vivo.38
In addition to kinetic inertness, a variety of other parameters can be tuned by changing
ligand structure. These parameters ultimately influence a measurable value of contrast-agent
efficiency called relaxivity, which has units of mM–1s–1. According to the Solomon–
Bloembergen–Morgan (SBM) equations that describe the behavior of T1-shortening contrast
agents, optimal relaxivity (r1) is achieved when the condition in Equation 1.1 is satisfied:2,3

Equation 1.1

ωI =

1

τR

+

1

τm

+

1
T1e

In Equation 1.1, ωI is the proton Larmor frequency, 1/τR is the rotational correlation rate,
1/τm is the bound-water exchange rate, and 1/T1e is the electronic relaxation rate of Gd3+. A
common magnetic field strength for the study of multilanthanide complexes is 0.47 T, which
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corresponds to a proton Larmor frequency of 20 MHz, whereas a common clinical field strength
is 1.5 T, which corresponds to a Larmor frequency of 64 MHz. While field strength influences
relaxivity, the trends that I will elucidate from the studies of multilanthanide complexes are valid
at clinical magnetic fields because at either field strength, the sum of 1/τR, 1/τm, and 1/T1e must be
on the order of 107 s–1 to achieve maximum relaxivity. Additionally, as magnet technology
improves and higher field strengths become available, optimal values of these three parameters
will need to be achieved through ligand design. The need to tune the structure of contrast agents
for MRI to reach specific values of the three parameters listed above has resulted in decades of
studies of monometallic lanthanide chelates, and several detailed reviews have been published on
this topic.39–41 Due to the multitude of studies focused on the relationship between the structural
features of lanthanide chelates and their corresponding ability to function as contrast agents, a
functional understanding of the effects of molecular structure on 1/τR, 1/τm, and, to a lesser
degree, 1/T1e has been developed. I will now describe the relationships between these parameters
and the structure of multilanthanide complexes.
Rotational Correlation Rate
The rotational correlation rate, 1/τR, describes the rotation of the Gd–H vector. Therefore,
both the global and local motions of chelates affect the magnitude of 1/τR. The local component
of 1/τR has been referred to as 1/τlO or 1/τR* and has been analyzed as a separate component from
the global 1/τR with the Lipari–Sazbo method.35,42,43 While higher molecular weights result in
slower values of 1/τR for monometallic chelates, this relationship is essentially nonexistent for
multilanthanide complexes of intermediate molecular weight such as those shown in Figures
1.3a and 1.3b. Studies on the behavior of intermediate to high molecular weight compounds with

multiple lanthanide chelates indicate that the local motion of one chelate relative to another
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Figure 1.3a. Multilanthanide complexes studied for use as contrast agents for MRI reported
since 2006. Due to a lack of data necessary for comparison to other complexes described in
this chapter, complex 1.10 is not discussed in the text.51 Coordinated water molecules have
been removed for clarity. Reprinted with permission from Moore, J.D.; Allen, M.J. Recent
Patents on Nanomedicine 2011, 1, 88–100. Copyright 2011 Bentham Science Publishers.
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Figure 1.3b. Multilanthanide complexes studied for use as contrast agents for MRI reported
since 2006. Due to a lack of relevant data, complexes 1.16 and 1.20 are not discussed in the
text.52,53 Coordinated water molecules have been omitted for clarity. Reprinted with
permission from Moore, J.D.; Allen, M.J. Recent Patents on Nanomedicine 2011, 1, 88–100.
Copyright 2011 Bentham Science Publishers.

limits the degree to which a high molecular weight can decrease 1/τR. An early study
demonstrated the influence of local motion on 1/τR and relaxivity using a cyclic moiety to bridge
two DO3A-type chelates (Figure 1.4).34 Relative to the more flexible linker on complex 1.24, a
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slightly higher relaxivity was achieved with 1.25. However, inspection of molecular structure
reveals that even the cyclic-linked structure retains some degree of freedom between chelates
due to potential ring inversion suggesting that even more rigidity is needed in linker design.
Analysis of recently reported dimetallic
O

O

complexes also reveals that 1/τR is not strictly
dependent on molecular weight. Of the 23
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Figure 1.4. Multilanthanide complexes
with nonrigid (1.24) and rigid (1.25)
linkages deviate from the MW–1/τR
relationship observed in larger complexes.
Reprinted with permission from Moore,
J.D.; Allen, M.J. Recent Patents on
Nanomedicine 2011, 1, 88–100. Copyright
2011 Bentham Science Publishers.

reveals no apparent relationship (Figure
1.5).35,44–50 The lack of a correlation between 1/τR and molecular weight may be due in part to the

narrow molecular weight range (1100–6000 Da) of this class of compounds, but it is also
attributable to the lack of a quantitative model to predict the degree to which the local motion of
the chelates contributes to 1/τR. For instance, inspection of 1.2 and 1.3 suggests that steric
repulsion between the chelates in 1.3 should restrict the local motion of the chelates relative to
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the chelates in 1.2.45 Therefore, 1/τR might
be expected to be slower for 1.3 than 1.2
due to a slower 1/τR*. However, 1/τR is 36%
slower for 1.2 than it is for 1.3. The reason
behind this apparent disagreement may be
that the hydrodynamic radius of 1.2 is
slightly larger than that of 1.3 due to paraversus meta-substitution of the linker. In
cases where the hydrodynamic radius can
be regarded as similar, such as for 1.3 and
1.4, the molecular weight appears to
correlate inversely with 1/τR.
Complexes 1.5–1.7 also show an
inverse correlation between 1/τR and

Figure 1.5. Comparison of molecular weight to
1/τR for complexes 1.1–1.8, 1.11–1.13, 1.15,
and 1.17. Values of 1/τR were determined by
fitting NMRD data acquired at 298 K. The
number at each point corresponds to the number
of the complex shown in Figures 1.3a and
1.3b. Reprinted with permission from Moore,
J.D.; Allen, M.J. Recent Patents on
Nanomedicine 2011, 1, 88–100. Copyright 2011
Bentham Science Publishers.

molecular weight.46 In this case, 1/τR and
relaxivity both follow the expected trends of decreasing and increasing, respectively, with
increasing molecular weight. Although the authors refer to the rigidity of the structure of 1.6
relative to 1.5 as an explanation for its slower 1/τR and higher relaxivity, it is important to note
that 1.6 also has the highest molecular weight of the three similar complexes.46 The influence of
molecular weight on 1/τR was not of particular interest to the study, which focused on CaII
binding, but demonstrates the combined effect of rigidity and molecular weight on 1/τR in
multimetallic species. The lessons learned from studying multilanthanide complexes indicate that
the rigidity of macromolecular structure is paramount to achieving maximum relaxivity;
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however, in spite of a qualitative understanding of the value of 1/τR, 1/τR for new multilanthanide
complexes is difficult to estimate. Further fundamental studies exploring the modulation of 1/τR
and 1/τR* are necessary to enable rational improvements to the design of multilanthanide and
macromolecular complexes as contrast agents for MRI. These improvements include the use of
ultra-high-field magnets that generate higher resolution images in shorter scan times, properties
that are likely to improve clinical diagnosis.
Water-Exchange Rate
Water-exchange-rate, 1/τm, is usually not the limiting factor in relaxivity for low to
intermediate molecular weight contrast agents. However, 1/τm becomes limiting as magnetic field
strength increases, and 1/τm will need to be modulated to generate effective contrast agents at
ultra-high magnetic field strengths (≥7 T). Methods of modulating 1/τm include changing ligand
basicity or changing the number of coordinating atoms.54–56 More basic chelates decrease Lewis
acidity of coordinated lanthanide ions, which in turn results in weaker water–lanthanide
interactions and a concomitant increase in 1/τm. Also, complexes formed from heptacoordinate
chelates typically exhibit a faster 1/τm than complexes formed with octadentate chelates,
consistent with an associative water-exchange mechanism allowed by the second available
coordination site. As a point of reference, 1/τm values for GdDOTA and GdDTPA are 4.1 × 106
s–1 and 3.3 × 106 s–1, respectively, an order of magnitude slower than optimal at 0.47 T and even
less optimal at higher fields.57 Therefore, a faster 1/τm is desirable regardless of field strength.
Values of 1/τm are especially important for higher molecular weight complexes where 1/τR is near
an optimal value and 1/τm begins to be the limiting factor in optimizing relaxivity.
The charge and denticity of a chelate are the primary structural features that affect 1/τm.
As many synthetic strategies have centered upon DO3A- or DTTA-type chelating moieties, the
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charge of the ligand is typically only determined by the charges of the substituents on the cyclen
or ethylene triamine backbone. Consequently, many multimeric ligands carry three acetate
groups per Gd3+ ion to form neutral complexes.
An alternative method to increase 1/τm is to sterically crowd the water-binding site.54–56
Designing a ligand that introduces steric interference without eliminating the coordinated water
molecule is a challenging task. As a result, little research has been conducted with an aim to
modulate water exchange in multilanthanide complexes, although several multilanthanide
complexes exhibit a faster water exchange rate compared to their monometallic counterparts. For
instance, 1.1 exhibits a nearly optimal 1/τm value of 1.9 × 107 s–1 at 0.47 T where ωI is 2.0 × 107
s–1.44 Complexes 1.3, 1.4, 1.7, and 1.15 have 1/τm values roughly an order of magnitude closer to
ωI than GdDOTA.45,46,49 The faster 1/τm for 1.3, 1.4, 1.7, and 1.15 can be attributed to the
associative exchange mechanism induced by the heptacoordinate chelates and is probably not
due to steric crowding. However, the steric effect of packing several chelates close together is
evidenced by the hydration number, q, of these complexes. Rather than the expected q = 2,
heptacoordinate chelates 1.3, 1.4, and 1.7 are monohydrated at each lanthanide.45,46
Conversely, complexes 1.8, 1.9, 1.11, and 1.12 have slower exchange rates than
GdDOTA and GdDTPA which can be attributed to the substitution of an acetate with an amide
attached to the linker.47,48 Therefore, the Lewis acidity of Gd3+ in these complexes is likely
greater compared to tetra- or pentaacetate analogues, leading to stronger water–Gd interactions.
However, the Lewis acidity of the Gd3+ ions is not the only factor affecting the water-exchange
rates observed for multilanthanide complexes.
Complex 1.13 is a unique example of a multilanthanide complex that contains three
DTTA-based chelates.35 Surprisingly, the water-exchange rate for 1.13 (1/τm = 9.01 × 106 s–1) is
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three times slower than that of the DO3A-based analog, 1.15 (1/τm = 32 × 106 s–1), even though
the Gd3+ ions in 1.13 are less Lewis acidic than those in 1.15.35,49 Further, 1/τm is slower in 1.13
than in 1.1, 1.3, 1.4, and 1.7, all of which are reported with q = 1 and would be expected,
therefore, to exchange water more slowly.35,44–46,49 It is not obvious what structural features
cause this difference in water-exchange rates and, in particular, what causes the water-exchange
rate of 1.13 to be slower than what we might expect relative to the DO3A-based 1.15. With this
difference in mind, it would be intriguing to compare the water-exchange rates of the
heptagadolinium β-cyclodextran-based 1.22 and 1.23 that presumably have high enough
molecular weights that the water-exchange rates will contribute to relaxivity.58–60 Complexes
1.22 and 1.23 differ in their chelates, and a comparison of their water-exchange rates would be

useful to study the effect of chelate structure on relaxivity. However, 1/τm was not reported for
these complexes.
In general, a challenge associated with directly studying water exchange in
multilanthanide complexes is the complexity of synthesizing multimeric ligands. However,
comparison of 1/τm to ωI at higher magnetic fields reveals that 1/τm may become limiting for
many multilanthanide complexes.2,3 Further, the relaxivity of macromolecular systems with 1/τR
approaching ωI will be limited by 1/τm indicating a need to optimize 1/τm in these larger systems;
therefore, there is a need in contrast agent research to address 1/τm modulation in multilanthanide
systems.
Gd3+ Electronic Relaxation Rate
The potential of multilanthanide complexes to be used as contrast agents for MRI should
be discussed noting that changes in electronic relaxation rate, 1/T1e, have been observed in
multilanthanide complexes.61–63 The electronic relaxation rate is typically estimated based on the
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zero field splitting parameter, Δ2, and the
electronic-relaxation correlation time, τv.64
Substituting the reported Δ2 and τv values
for GdDOTA into Equation 1.2,64 we
calculated 1/T1e for field strengths from 0.5
to 10 T and plotted these values and ωI
versus field strength (Figure 1.6). Equation
1.2 is considered to be valid only in the
range where ωs2τv2<<1, where ωs is the
electron Larmor frequency and S is the Gd3+
electron spin (S = 7/2).64 Therefore, these
values are our best estimate due to the lack
of empirical analysis of 1/T1e outside this
range. Comparison of the two functions

Figure 1.6. Plot of ωI (♦) and 1/T1e for
GdDOTA (■) over the low to ultra-high
magnetic field strength range. The gray bar
represents the range of field strengths at which
most multilanthanide complexes have been
studied up to common clinical field strengths.
Reprinted with permission from Moore, J.D.;
Allen, M.J. Recent Patents on Nanomedicine
2011, 1, 88–100. Copyright 2011 Bentham
Science Publishers.

shows that 1/T1e is 750% faster than optimum at 1.5 T. While 1/T1e is an order of magnitude
closer to ωI than 1/τR for the monometallic GdDOTA, 1/T1e and 1/τR are on the same order of
magnitude (109 s–1) for several multilanthanide complexes. Of the complexes presented in this
review, four have 1/T1e-limited relaxivity based on a comparison of 1/τR, 1/τm, and 1/T1e values. It
is likely that 1/T1e is also limiting for higher molecular weight complexes. While the need to
understand and manipulate 1/T1e is apparent, studies of monometallic Gd3+-containing complexes
to determine structural features that influence electronic relaxation have been inconclusive.
Interestingly, the study of multilanthanide complexes could contribute to the improvement of
contrast agents through increasing our understanding of 1/T1e.
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Equation 1.2

2
⎡
⎤
1 τ vΔ
[4S ( S + 1) − 3] ⎢ 1 2 2 + 4 2 2 ⎥
=
25
T1e
⎣1 + ω s τ v 1 + 4ω s τ v ⎦

Previous reports describing multilanthanide complexes have suggested a dipolar
relaxation mechanism as an explanation for shorter 1/T1e values in multimetallic systems.62–63
However, if a dipolar relaxation mechanism is responsible for modulating 1/T1e in
multilanthanide complexes, 1/T1e will likely depend on Gd–Gd distances and could be studied
with a series of identical chelates and variable-length linkers. The results of these studies would
enable the rational synthesis of systems with optimized 1/T1e to fulfill the condition in Equation
1.1. Currently, the design of macromolecular lanthanide-containing complexes for contrast
agents is essentially limited to attempts to optimize 1/τR and 1/τm.
Although previous studies of dinuclear complexes 1.5–1.7 did not focus on electronicrelaxation rate,46 I made an effort to elucidate a relationship between the distance separating the
chelates (estimated by the number of atoms between Gd3+ ions) and 1/T1e (calculated from
reported Δ2 and τv values and Equation 1.2). My choice to compare only complexes 1.5–1.7 is
based on the similarity in structure of the chelates and linkers. Other complexes were not
considered part of the series due to the lack
of structural similarity or published data. In
complexes 1.5–1.7, 1/T1e decreases from
complex

1.7

(16-atom-separation)

to

complex

1.5

(19-atom-separation)

to

complex 1.6 (24-atom separation) (Table
1.1).

Table 1.1. Comparison of the distance
between Gd3+ chelates to calculated electronic
relaxation times at 0.47 T.46 Reprinted with
permission from Moore, J.D.; Allen, M.J.
Recent Patents on Nanomedicine 2011, 1, 88–
100. Copyright 2011 Bentham Science
Publishers.
Complex
1.7
1.5
1.6

Atom Separation
16
19
24

T1e (ps)
41.5
58.5
87.0
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The purpose of this observation is not to make conclusions or a quantitative assessment
of the data but to present the possibility that, with further study of multimetallic and in particular
dimetallic lanthanide complexes, a method to modulate and understand 1/T1e could be developed.
Currently, the absence of empirical data and direct experimental techniques to interrogate 1/T1e
represents a challenging opportunity for exploration. Gaining a fundamental understanding of
1/T1e is necessary to improve contrast agents for current clinical fields and to understand how
effective high-field contrast agents can be synthesized.
Hydration Number
Another important factor in determining relaxivity is the hydration number of the
lanthanide, q. Based on the SBM equations, r1 scales directly with q.3 As mentioned, the
disadvantage of chelates with a hydration number greater than one (with a few exceptions, see
reference 65) is that these complexes tend to be kinetically labile and, therefore, toxic. Despite
this limitation, researchers have synthesized multilanthanide complexes with linking moieties
that do not contribute a coordinating atom, resulting in q = 2 chelates. This design has resulted in
some of the highest relaxivity multilanthanide complexes such as 1.13 (r1 = 15.70 mM–1s–1Gd–1,
310 K, 0.47 T).35 However, these dihydrated metal ions will likely be limited to preclinical
studies because of their labile nature.
PARACEST MRI

In the last decade, paramagnetic chemical exchange saturation transfer (PARACEST)
agents have been developed for MRI.66–68 A PARACEST agent is a molecule that has
exchangeable protons (for example alcohols, amides and metal-bound water) that are shifted by a
paramagnet. Paramagnetic substances such as lanthanide ions are able to shift some
exchangeable protons 100 parts per million (ppm) or more.66–68 Detailed reviews on the
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mechanism of PARACEST and lanthanide-based PARACEST agents are available;66–69
therefore, I will only briefly describe the features of PARACEST agents that are relevant to
multilanthanide systems.
PARACEST imaging relies on the exchange of one or more protons from a paramagnetic
complex with protons from the bulk water. A PARACEST image is generated by subtracting two
maps of bulk-water-peak intensity: a reference map acquired without a presaturation pulse and a
map acquired after a presaturation pulse at the resonance frequency of the exchanging protons.
The PARACEST image is the difference in bulk-water-peak-intensity between the reference and
presaturated maps. Because the PARACEST phenomenon causes a decrease in bulk-water peak
intensity, the scale of a PARACEST image represents the degree of bulk-water-peak
suppression.
The efficiency of a PARACEST agent is determined by two factors: (1) the protonexchange rate, kex, and (2) the difference between the exchanging-proton and bulk-water
chemical shifts, Δω.66–69 For a paramagnetic substance to effectively transfer saturated protons to
the bulk water, kex should be less than or equal to |Δω|.66–69 Therefore, greater differences in
chemical shift (large Δω) allow for faster proton-exchange rates. PARACEST imaging is
advantageous compared to T1- and T2-based MRI because there is no background signal in a
PARACEST image. However, like other MR imaging techniques, PARACEST imaging is
insensitive and requires a high concentration (mM) of agent to generate satisfactory images.
Therefore, an agent with a large number of exchangeable protons is desirable for decreasing the
concentration of agent required.70,71
Of reported PARACEST agents, only two dimetallic lanthanide complexes fit the
category of complexes described in this review. Complex 1.26 (Figure 1.7) contains 12 amide
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protons with chemical shifts that are shifted 12 ppm from the bulk water peak.72 Although this
shift is small and partial overlap with the bulk water peak exists, a PARACEST effect was
observed to reduce the bulk water signal by 30% for a 10 mM solution of complex 1.26.72 With
complex 1.27, PARACEST is due to the exchange of coordinated and bulk water molecules
(Figure 1.7).73 The chemical shift of the coordinated water protons is shifted 45 ppm from the
bulk water signal, and a 30% reduction in the bulk-water signal was observed for a 10 mM
solution of complex 1.27.73 This result is similar to the PARACEST effect observed for a
EuDOTA tetra(amide) mononuclear analog,29 indicating that the effect is not augmented by the
presence of the second chelate. A potentially more useful molecule may contain two covalently
linked amide-based chelates and, therefore,
double the number of exchanging water
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we expect that these ligands could be useful for making PARACEST agents with lanthanides
other than Gd3+. The use of these multimeric ligands in PARACEST agents has not been
reported, but the water-exchange rates reported for their Gd3+ complexes indicate that their
complexes with other lanthanides could be useful as PARACEST contrast agents for MRI.
Studies of multilanthanide systems will likely lead to an understanding of how a sufficient
chemical shift of a large number of exchangeable protons can be achieved. This understanding
has the potential to be applied to macromolecules that contain many exchangeable protons and,
therefore, produce highly sensitive PARACEST contrast agents.
Multilanthanide-based Luminescent Probes

While lanthanides other than Gd3+ are used in PARACEST imaging, they also lend
themselves to optical imaging. Lanthanides exhibit luminescent behavior that results from 4f
electronic transitions.74 These transitions are Laporte forbidden and result in narrow, low
intensity emission bands compared to organic fluorophores. The narrow line width of lanthanide
emission peaks generates characteristic emission spectra that enable identification of lanthanidebased probes. Additionally, the lifetimes of lanthanide emissions can be on the order of micro- to
milliseconds, much longer than organic molecules including biomolecules.74–79 These
exceptionally long luminescence lifetimes are the key advantage to lanthanide-based probes for
medical applications.74–79 Background autofluorescence from organic biomolecules decays much
faster than lanthanide luminescence such that a delay between excitation and detection in an
imaging experiment will eliminate non-lanthanide-based background fluorescence. The
possibility that zero-background images could be acquired using luminescent lanthanide probes
makes their study a worthwhile pursuit to the medical field. Luminescent lanthanide complexes
that are responsive to medically relevant biochemical events could become useful diagnostic
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probes based on specific molecular-level interactions. Probes based on these interactions have
the potential to improve the precision, accuracy, and ease-of-use of diagnostic assays. Further,
use of kinetically inert complexes such as those discussed in this review might allow diagnoses
in vivo.
Multilanthanide complexes with Eu3+ and Tb3+ have been studied due to their long
luminescence lifetimes (110 to 400 μs) and their intense emission bands (relative to other
lanthanides) in the visible region. For in vivo imaging emission in the visible region may be
viewed as a limitation due to minimal tissue penetration of emitted wavelengths that require
invasive detection methods. Yb3+ complexes emitting in the near-IR region have also been
reported to address the issue of improving the tissue depth at which luminescence can be
detected.80 However, due to the similar coordination chemistry throughout the lanthanide series,
the study of Eu3+ and Tb3+ complexes is necessary to determine many structural parameters and
provide proof-of-concept for detecting a response. Other lanthanides are typically not strong
emitters and have not been reported multilanthanide complexes for these applications,
presumably for this reason.
Ligand Design
Although considerations to prevent lanthanide toxicity using polydentate chelates are
necessary for luminescent probes, three other factors also must be considered for the design of
multilanthanide complexes for luminescence-related applications. First, OH and NH oscillators
are efficient quenchers of Ln3+ luminescence; therefore, to preserve long Ln3+ luminescent
lifetimes, polydentate chelates must not contain OH or NH oscillators in the inner coordination
sphere of the metal ion.75–77,81 Second, the low quantum efficiency of Ln3+ ions can be improved
with ligands containing organic fluorophores (antennas) that absorb and transfer energy to Ln3+
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excited states.75–77,81,82 Third, without interactions with substrates, luminescent lanthanide
complexes have little use in medicine; therefore, ideally, the emission intensity or wavelength
will change upon the interaction of a substrate with the complex. Ln3+ ions are strong Lewis
acids and are capable of binding to a wide variety of anions; however, useful sensing
applications require that binding be specific, which requires control of the Ln3+ coordination
sphere through judiciously designed ligands. Alternatively, a complex can be designed to bind to
an analyte of interest and detection can take place after unbound complex has been washed or
diffused away. This strategy has not been reported for multilanthanide systems and represents an
unexplored area of future research.
The synthesis of multimeric ligands tends to be more challenging than the synthesis of
monomeric ligands; however, the sensitivity of Ln3+ luminescent probes can be increased by a
simple additive effect when multiple Ln3+ ions are present in one complex. Another possible
advantage of multilanthanide complexes is Ln3+-sensitized luminescence.80 In these systems,
interactions at each lanthanide can be interrogated separately for ratiometric sensing, wherein the
response of the probe can be determined without determining the concentration of the probe.83
Further, some multilanthanide complexes are known to display different properties than their
monometallic analogs such as a response to or cleavage of DNA and RNA for reasons that are
not well understood.48,83,84 Yet, while the study of interactions between multilanthanide
luminescent probes and DNA is still in its infancy, this class of compounds has the potential to
generate useful tools for gene sensing or for therapy in the medical field.
Antennas
Ligands appended with organic fluorophores improve the quantum yield of lanthanide
complexes. This improvement is due to more efficient excitation of the chromophore relative to
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direct excitation of the lanthanide,
as illustrated in Figure 1.8. The
specific processes involved in the
transfer of energy from the ligand
excited state to the lanthanide
excited state depend on the relative
energies of the donor and acceptor
states and detailed reviews of this
phenomenon

are

elsewhere.75,77,78,81
multilanthanide

available
Nearly

all

complexes

Figure 1.8. Illustration of the excitation and emission
processes of a lanthanide ion by direct excitation (top
left) and antenna-sensitized excitations (top right).
Simple Jablonski diagram of lanthanide excitation and
emission processes during direct excitation (bottom
left) and antenna-sensitized excitation (bottom right).
Reprinted with permission from Moore, J.D.; Allen,
M.J. Recent Patents on Nanomedicine 2011, 1, 88–100.
Copyright 2011 Bentham Science Publishers.

synthesized for medical sensing
applications contain an antenna in the linker (Figure 1.9). Complexes 1.28 and 1.30–1.40
contain aromatic groups that function as antennas within these linkers.83–87 The efficiency of
energy transfer depends in part on the Ln3+–antenna distance; therefore, antennas that coordinate
to the Ln3+ ion such as the pyridyl ligands in 1.32 are expected to better sensitize Ln3+ emission
than those that transfer energy through space. An additional requirement for the antenna is that
the excited energy state must be higher than the Ln3+ excited state and must be sufficiently
higher in energy to prevent back energy transfer. Therefore, the antenna excited state should lie
at least 1200 cm–1 above the emissive lanthanide excited state.88 Many conjugated systems other
than those shown in Figure 1.9 could be used as antennas as long as the excited-state energy
level of the antenna is matched to the lanthanide. Due to the wide variety of possible antennalanthanide combinations, the study of multilanthanide luminescent probes is expected to expand
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in the future. Another interesting observation in multilanthanide luminescent probes is that a
single fluorophore is capable of sensitizing two Ln3+ ions as demonstrated in complexes 1.28 and
1.33–1.40.83–85 The knowledge gained from studying how multiple lanthanide ions are sensitized

by a single antenna is likely to indicate how macromolecular systems can be designed with
multiple lanthanide ions excited by a single antenna. This type of design would be advantageous
over multiple-antenna-containing systems by minimizing the complexity of the macromolecular
structure.
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Figure 1.9. Multilanthanide complexes studied as luminescence probes discussed in this
review. Coordinated water molecules have been omitted for clarity. Reprinted with
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Luminescence Sensing
Adding functionality to multilanthanide complexes brings additional complexity to the
design and synthesis of multimeric ligands. The majority of multilanthanide luminescent probes
have been synthesized with tetraamide chelates (Figure 1.9). Tetraamide chelates are strong
Lewis acids that are potentially useful as anion sensors due to strong binding to negatively
charged substrates relative to their neutral counterparts. Dimetallic lanthanide complexes are of
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particular interest because they have been reported to exhibit different anion-binding
characteristics than their monometallic analogs.83,84 Sensing anions may be useful in determining
ion concentrations, which can be indicators of metabolism and homeostasis in cells, and
understanding cellular processes may facilitate identification of cellular abnormalities that could
be used to understand and diagnose disease. For example, complexes 1.28–1.31 and 1.33–1.36
bind anions such as phosphates and dicarboxylates through Lewis acid–Lewis base
interactions.83–85,87,89 Alternatively, the sensing of cations, especially toxic species such as HgII,
is of interest for determining contaminant levels in vivo and ex vivo. For this reason, complex
1.32 was studied, and it was found to show a change in luminescence in the presence of the HgII

cation.86 The luminescence response is due to the pyridyl groups that leave the Ln3+ coordination
sphere to bind to HgII.86 Of all substrates that have been studied with multilanthanide complexes,
perhaps the most intriguing and potentially useful to the medical field is DNA. Complex 1.39
was reported to show luminescence changes in the presence of DNA.83 This exciting result
indicates that the development of gene-specific medical assays may be possible. However, how
the interaction with DNA is effected by the structural characteristics of complex 1.39 is not well
understood. While further investigation of the interaction of DNA with 1.39 is underway, studies
exploring DNA-binding with new multilanthanide complexes will be useful to elucidate the
structural features that are responsible for the DNA interaction.
As mentioned, sensitizing multiple Ln3+ ions using one fluorophore has been
demonstrated.83–85 While double Ln3+ sensitization is fundamentally interesting, it could be
especially useful with heterometallic complexes. Hetero-multimetallic complexes would be ideal
for ratiometric sensing where one Ln3+ emission remains constant while the others change in
response to a substrate. Ratiometric sensing would eliminate the need to know the concentration
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of the probe, making in vivo analysis of substrates such as cations, anions, and DNA possible
where the probe concentration is unknown.
Literature Summary

The study of multilanthanide complexes is a necessary endeavor in pursuit of advanced
medical diagnostics. Substantial contributions have been made to the fields of MRI and
luminescence imaging by studying multilanthanide complexes. Continued study of these
complexes will facilitate our understanding of the fundamental relationship between chemical
structure and imaging properties. This knowledge is needed to enable the rational design of
optimized complexes for medical applications. These complexes will likely contribute to the
field of medical imaging in the form of ultra-high field contrast agents for MRI, activatable
probes for MRI, and luminescent in vivo molecular imaging for personalized medicine.
Research Approach

While considerable effort has been exerted in studying multilanthanide systems with the
complexes shown above, there were only a few examples where the distance between lanthanide
ions was within what is required for Ln–Ln interactions (through space dipole–dipole
interactions are a function of the inverse distance to the sixth power and orbital coupling
essentially requires that the ions be touching or bridged). Though many examples of bridged
lanthanide complexes are reported, few have been studied for and satisfy the aqueous stability
requirements necessary for medical applications. There was also a lack of understanding and
focus on the cumulative effects of binding two lanthanides within a few angstroms of each other,
though extensive work in solid-state and extended-solid systems has been published on Ln–Ln
interactions. The absence of an available system to probe the effects of inter-lanthanide distance
and study the properties of bridged complexes in an aqueous environment, where novel
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properties may be especially useful, lead me to design and synthesize a new ditopic ligand and
corresponding lanthanide complexes.
In Chapter 2, I will illustrate the important features of the ligand and discuss the rationale
behind the ligand design that lead me to expect that aqueous-stable, bridged, dimetallic
lanthanide complexes could be generated with this ligand. I will also discuss the expected
properties and potential applications of the resulting complexes that guided my selection of
lanthanide ion used in the complexes I have made. In Chapter 3, I will present the luminecence
behavior of the Eu3+ complex pertaining to pH-sensing applications along with optimized
structures and a possible mechanism of pH-response. Chapter 4 will describe further structural
analyses of dimetallic lanthanide complexes and the discovery of intramolecular lanthanidelanthanide energy transfer phenomena. In Chapter 5, I will summarize the results reported in the
Chapters 2–4 and relate these results to previously reported dimetallic complexes mentioned in
Chapter 1. I will also discuss the potential applications of this work for sensing and imaging
applications. I will conclude in Chapter 6 by discussion the impact that these results may have on
our fundamental understanding of and future work on aqueous lanthanide-based systems,
particularly in dimetallic and multimetallic lanthanide complexes. Finally, I will close with a few
suggestions for future experiments and alterations to the ligand for new dimetallic lanthanide
complexes.
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CHAPTER 2: Ligand Design and Synthetic Attempts
Ligand Design
The structure of the ligand I designed is based on several considerations. First, the
potential applications of the resulting metal complexes would require kinetic and thermodynamic
stability. Second, the study of lanthanide–lanthanide (Ln–Ln) interactions would require a close
proximity for metal binding sites. Third, the position of an alcohol between the binding sites
would facilitate a bridge between the Ln3+ ions, leading to unique properties (relative to
monometallic complexes) in a discrete dimetallic complex. The combination of these
considerations led me to propose a ligand containing two 1,4,7,10-tetraazacyclododecane-1,4,7triyl)triacetate (DO3A) moieties bridged by a 2-propanolyl linker (Figure 2.1).
The ligand is composed of three components:
cyclen macrocycles, carboxylate arms, and a 2-propanolyl
linker. Cyclen-based polyaminopolycarboxylate chelates
take advantage of the chelate and macrocyclic effects to
generate highly kinetically and thermodynamically stable
3+

complexes with Ln
functionalized

with

2, 3 ,39

ions.

many

Though cyclen has been
substituents

containing

Figure 2.1. Structure of ditopic
ligand 2.1, designed to bridge
two Ln3+ ions with an alcohol
donor.

functional groups that coordinate to lanthanides,34, 44, 47, 48, 86 often called ‘arms’, carboxylates
were chosen because they are known to be the strongest-binding organic donors and give the
ligand and overall charge of –6, which results in a neutral complex when bridging two Ln3+ ions
if the alcohol remains protonated. Finally, because Ln3+ prefer coordination within a fivemembered ring, the choice of a 2-propanolyl linker places an alcohol donor in an ideal position
to form fused five-membered rings with two Ln3+ ions, facilitating a desired alcohol bridge.
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Synthetic Approach
My initial retrosynthetic analysis of 2.1 suggested that a two-step synthetic route could
yield the desired product (Scheme 2.1). The first reaction would require two nucleophillic
Scheme 2.1. Two-step retrosynthesis of the 2-propanolyl-bridged ditopic ligand.

substitutions to 1,3-dibromo-2-propanol with commercially available DO3A-tris-tert-butyl ester,
2.3, generating protected ligand 2.2. The tert-butyl ester protecting groups could be removed
from 2.2 with trifluoroacetic acid to yield H62.1. The experimental conditions for the first
reaction were varied, and a list of the attempted conditions is described in Table 2.1; however,
no evidence for the formation of the desired product 2.2 was observed by thin layer
chromatography (TLC), NMR spectroscopy, or mass spectrometry. Mass analysis of the reaction
mixtures listed in Table 2.1 revealed that a possible side reaction was occurring after one
substitution of 1,3-dibromo-2-propanol to yield a species with 571 m/z through an unknown
mechanism (Scheme 2.2). I hypothesized that the formation of these side products could be
limited by reducing the reaction temperature;
however, only a trace amount of 2.2 was detected
when the reaction was carried out at ambient
temperature.

The

second

substitution

likely

requires a higher temperature to overcome steric
interference

caused

Scheme 2.2. Potential products with 571
m/z that inhibited formation of the
desired product, 2.2.
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by the first macrocycle; consequently, I modified my proposed synthesis to account for this
limitation. In my second and third synthetic attempts (Scheme 2.3 and 2.4, respectively), I used
more compact macrocycles in an attempt to reduce steric interference in the second substitution.
I reasoned that less steric interference would enable the use of lower temperatures and minimize
side reactions. The following syntheses also represent a shift in strategy toward adding the
carboxylate arms after forming the propanolyl-bridged di-cyclen skeleton, 2.8 (Scheme 2.3).
One less-hindered cyclen-containing nucleophile that I used was (1,4,7-trisbutoxycarbamate)1,4,7,10-tetraazacyclododecane (2.4), illustrated in Scheme 2.3. Due to the
decreased steric bulk of the tert-butoxycarbamate (BOC) protecting groups compared to the tertbutyl acetate arms, the reaction between 2.4 and 1,3-dibromo-2-propanol was expected to
proceed at lower temperature than with 2.3, potentially reducing the elimination side reaction.
However, the desired product, 2.5, was not observed at ambient temperature or upon heating at
reflux in acetonitrile, and the elimination product was observed after heating.
Scheme 2.3. Attempted route to synthesize 2.8 using tris-BOC-cyclen (2.4).

A more successful approach to making the bis-cyclen propanol skeleton, 2.8, was via the
reaction of cis-decahydro-2a,4a,6a,8a-tetraazacyclopentacenaphthylene (2.6) with 1,3-dibromo2-propanol (Scheme 2.4). The reaction proceeded at ambient temperature in acetonitrile to form
a di-ammonium bromide salt that precipitated from the reaction mixture and could be isolated by
filtration. This result was expected based on the work of Le Baccon and coworkers who reported
similar reactions with other alkyl dibromides.90a Deprotection of 2.7 was carried out in 20%
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aqueous KOH by heating to 60 °C for 3 days.90b Isolation of pure 2.8 was achieved by direct
extraction of the reaction solution with chloroform. Alkylation of 2.8 was attempted under
multiple conditions with a range of bases, solvents, alkylating agents, and temperatures. In
general, reactions carried out at temperatures between 20 and 45 °C resulted in incomplete
alkylation. Reactions carried out at higher temperatures resulted in over alkylation. The overalkylated products were not separable from 2.2. More importantly, observation of a seven-arm
product forced me to consider that the alcohol might be alkylated, possibly producing 2.9 and
2.10 (Scheme 2.4). Therefore, I had no way of knowing whether the observed six-arm product
was the result of alkylation at the six secondary amine positions or at five secondary amines and
the alcohol. Despite my initial assumption that O-alkylation was unlikely, the structures of the
six-arm products 2.2, 2.9, and 2.10 could not be deconvoluted or positively identified.
Subsequently, I devised several approaches to mask the alcohol so that only the N-alkylated
product could be obtained, which I will describe in the next three sections.
Selective O-protection
Scheme 2.4. Bis-aminal-cyclen-based synthesis of 2.2.
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I considered the C–N bonds from the cyclen moieties to the propanol bridge to be the key
bonds for the formation of ligand 2.1. Therefore, it appeared that compound 2.8, in which those
bonds were already formed, would be the most viable starting point. However, selective
protection of the alcohol in the presence of six secondary amines posed a significant challenge
due to the nucleophilicity of the amines. Thus, I first attempted to mask the alcohol using the
tetrahydropyranyl protecting group that can be installed under acid-catalyzed conditions. To
achieve an acidic solution of compound 2.8, approximately 10 equivalents of acid were required.
Adding this amount of acid resulted in the precipitation of the protonated form of 2.8 from
solvents including CH3CN, CHCl3, MeOH, EtOH, and tetrahydrofuran, with which the
protecting group reagent, dihydropyran (DHP), is miscible. In retrospect, I think this reaction
might be possible in dimethylformamide (DMF) or dimethylsulfoxide (DMSO) where both DHP
and the salt of 2.8 might be soluble.
I also attempted selective O-protection with trimethylsilyl chloride (TMSCl) because
silylamide moieties are labile and can be removed during a workup. I found isolation of the
trimethylsilylether to be impossible, and I could not detect such a product with mass
spectrometry or NMR spectroscopy. Attempts to treat compound 2.8 with TMSCl immediately
followed by tert-butylbromoacetate under basic conditions were unsuccessful in yielding
protected ligand 2.2 or its TMS ether derivative. At this point, it was clear that continuing to use
compound 2.8 as an intermediate would require a more complex strategy to prevent Oalkylation—global protection, selective O-deprotection, orthogonal O-protection, and selective
N-deprotection might be necessary. While exploring this iterative protecting group strategy, I
synthesized three precursors—2.11, 2.12, and 2.13—to protected ligand 2.2 by protecting 1,3-
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dibromo-2-propanol (Scheme 2.5). Although the iterative strategy might have been successful,
the success of less convoluted routes caused me to abandon the iterative approach.
Scheme 2.5. Syntheses of protected 1,3-dibromo-2-propanol and ligand intermediates.
O

O

OBn

Br

2.3, K2CO3, CH3CN, reflux

N

N

N

N
t-BuO

O
Ot-Bu

N

N

2.11

N

OBn

N

21%

Br

Ot-Bu

Ot-Bu

Ot-Bu
O

t-BuO
O

O

2.16
O

O

OAc

Ac2O, pyridine

Br

O

t-BuO

t-BuO
O

O

2.17

TESOTf, pyridine

O

O

OTES

Br

O

2.3, K2CO3, CH3CN, reflux

Br

2.13

Ot-Bu

Ot-Bu

Ot-Bu

97%

O
Ot-Bu

N

N

2.12

OH

Br

N

N

91%

Br

N

OAc

N

20%

Br

N

N

2.3, K2CO3, CH3CN, reflux

Ot-Bu

Ot-Bu

Ot-Bu

N

N

20%

N

OTES

N

N

N
N
t-BuO

N

O
Ot-Bu

t-BuO
O

O

2.18

Propanone as an Alternative Bridge
In a simultaneous effort to remove the possibility of side reactions, I attempted to bridge
two DO3A moieties using a 2-propanonyl bridge (Scheme 2.6). There were several reasons to
consider this strategy: first, the halo-carbon sites of 1,3-dihaloacetone were expected to be more
electrophilic than those of 1,3-dihalo-2-propanol; second, the methyne carbon and alcohol
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oxygen atoms involved in side product formation from 1,3-dibromo-2-propanol are masked in
the ketone analog; and third, like alcohols, ketones are known to coordinate to lanthanides. To
install such a bridge, I reacted 1,3-dichloroacetone or 1,3-dibromoacetone with protected DO3A,
2.3, under basic conditions. The reaction mixtures immediately turned dark brown upon addition
of either 1,3-dihaloacetone to 2.3. The desired product 2.14 could not be detected by mass
spectrometry despite the consumption of the electrophile. Due to this surprising result, I exposed
1,3-dichloroacetone and 1,3-dibromoacetone to a series of bases, including nucleophillic
(NH4OH, H2O, 2.3, and 2.4)

and non-nucleophillic (TEA, DIEA, and K2CO3) examples. In

each case, the reaction mixture turned brown and the ketone was consumed. These results
suggested that dihaloacetones were unstable in the presence of base and could not be used to
successfully form 2.14. Therefore, this method and any other approaches to synthesize 2.14 were
not pursued further.
Scheme 2.6. Attempted synthesis of the protected propanonyl-bridged ligand.

Protecting Dibromopropanol Prior to Alkylation
After searching for a protecting group that could mask the alcohol during alkylation, I
suspected that a benzyl ether was the only protecting group that could withstand the harsh
conditions used to convert 2.7 to 2.8. Installation of the benzyl group directly on 1,3-dibromo-2propanol was not possible, and the 1,3-dibromo-2-propylbenzylether needed to be synthesized in
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four steps (Scheme 2.7).91 After using trityl groups to protect the primary alcohols of glycerol,
the secondary alcohol was protected as a benzyl ether, yielding 2.15. Trityl deprotection
followed by bromination yielded the desired 1,3-dibromo-2-propylbenzylether, 2.11. The
reactions in Scheme 2.4 were repeated, substituting 2.11 for 1,3-dibromo-2-propanol. Over
alkylation of 2.8 was observed, but the desired protected ligand, 2.16, was isolated. However,
Pd-catalyzed hydrogenation of the benzyl ether was unsuccessful. Simultaneous hydrolysis of the
benzyl ether and the six tert-butyl ester groups with HBr produced an uncharacterizable black
tar. This result, coupled with the success of other routes, caused me to abandon the synthesis of
an O-protected bis-cyclen skeleton in favor of protecting-group methods described in the
following section.
Scheme 2.7. Synthesis of benzyl-protected 1,3-dibromo-2-propanol, 2.13.
OH

OH

OH

TrCl, pyridine
quantitative

OH

OBn

BnBr, NaH, THF
48%

TrO

OTr

TrO

10% aq H2SO4,
1,4-dioxane
90%

OTr

2.15

OBn

OH

OH

OBn

PPh3, CBr4, CH2Cl2
90%

= Tr, trityl
Br

Br

2.11

Revisiting the 2.3 Nucleophile
The goal of the previous methods was to avoid the elimination product that hampered the
route using 2.3 to substitute 1,3-dibromo-2-propanol.

However, with the 1,3-dibromo-2-

propylbenzylether in hand, I reacted it with 2.3 to probe the effect of the protecting group on the
outcome of the reaction with respect to elimination. Though the elimination product was
detected, the desired product was produced in sufficient quantity to isolate. This success was
surprising because I had supposed that adding a protecting group to the alcohol would increase
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the steric bulk around the electrophilic sites and thereby hinder the substitution reaction. Based
on my experiments with 1,3-dibromo-2-propylbenzylether, the presence of an O-protecting
group on 1,3-dibromo-2-propanol has little impact on substitution reactions at the adjacent
carbon atoms. Therefore, I synthesized a series of 1,3-dibromo-2-propanol derivatives containing
protecting groups that could be more easily removed than the benzyl group.
One such protecting group was the acetate ester, which was easily installed under mildly
basic conditions using acetic anhydride to yield 2.14 (Scheme 2.5). However, the acyl group was
prone to acyl transfer to 2.3 during the subsequent reaction, resulting in low yields of 2.17 and
challenging purification. Elimination was also observed with the acyl protecting group. Because
the side reaction was still competing with substitution, I explored electron-donating protecting
groups rather than electron-withdrawing groups. The most electron-donating protecting groups
for alcohols are silyl ethers. The trimethylsilyl ether decomposed during alkylation of 2.3, but the
triethylsilyl (TES) ether proved to be robust enough to withstand the alkylation and purification
conditions to yield the desired protected ligand, 2.18, in 20% yield after purification by
chromatography (Scheme 2.5). Though the yield did not improve relative to using 2.14, the TES
protecting group made purification easier due to the lack of acetylated 2.3.
Experimental Procedures
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Water was purified using a PURELAB Ultra
Mk2 water purification system (ELGA). Tri-tert-butyl-2,2',2''-(1,4,7,10-tetraazacyclododecane1,4,7-triyl)triacetate (2.3) was prepared according to a published procedure.92 (1,4,7-trisbutoxycarbamate)1,4,7,10-tetraazacyclododecane (2.4) was purchased (Macrocyclics Inc.) and
used without further purification. Cis-decahydro-2a,4a,6a,8a-tetraazacyclopentacenaphthylene
(2.6)

was

prepared

according

to

a

published

procedure.90a

[[2-bromo-1-
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(bromomethyl)ethoxy]methyl]-benzene (2.11) was prepared according to a published
procedure.91 [(1,3-Dibromopropan-2-yl)oxy]triethylsilane (2.13) and {[1,3-di(DO3A-tert-butyl
ester)-2-yl]oxy}triethylsilane (2.18) were prepared according to the procedures listed in Chapter
3 for compounds 3.2 and 3.3, respectively.93
Flash chromatography was performed using silica gel 60, 230–400 mesh (EMD
Chemicals). Analytical thin-layer chromatography (TLC) was carried out on ASTM TLC plates
precoated with silica gel 60 F254 (250 μm layer thickness). TLC visualization was accomplished
by charring with potassium permanganate stain (3 g KMnO4, 20 g K2CO3, 5 mL 5% w/v aqueous
NaOH, 300 mL H2O) or by charring with ceric ammonium molybdate stain (4 g cerium(IV)
sulfate hydrate complex with sulfuric acid, 100 g ammonium molybdate tetrahydrate, 900 mL
H2O, 100 mL concd H2SO4). A sonicator (Fisher FS60H) cooled with a homemade heatexchanger to maintain ambient temperature was used for ultrasonic agitation.
1
13

H NMR spectra were obtained using a Varian Unity 400 (400 MHz) spectrometer, and

C NMR spectra were obtained using a Varian Unity 400 (101 MHz) spectrometer. Chemical

shifts are reported relative to residual solvent signals (CDCl3: 1H: δ 7.26, 13C: δ 77.23; H2O: 1H:
δ 4.79; H2O/CH3CN: 1H: δ 4.79, 13C: δ 1.30; CD3CN: 1H: δ 1.94, 13C: 1.30). 1H NMR data are
assumed to be first order, and the apparent multiplicity is reported as “s” = singlet, “d” =doublet,
“quin” = quintet, and “m” = multiplet. Italicized elements are those that are responsible for the
shifts. High-resolution electrospray ionization mass spectra (HRESIMS) were obtained using an
electrospray time-of-flight high-resolution Waters Micromass LCT Premier XE mass
spectrometer.
8a,8a''-(2-hydroxypropane-1,3-diyl)bis(decahydro-2H-2a,4a,6a,8a-tetraazacyclopentaacenaphthylenium) bromide (2.7): A solution of 2.6 (584.7 mg, 3.010 mmol, 2.2 equiv) and 1,3-
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dibromo-2-propanol (298.1 mg, 1.369 mmol, 1.0 equiv) in anhydrous acetonitrile (5.5 mL) was
prepared and sonicated at ambient temperature under Ar. A pale brown solid slowly precipitated
over the course of the reaction. After 15 days, the reaction mixture was filtered through
Whatman #1 filter paper. The precipitate was washed with acetonitrile (5 × 15 mL). The
precipitate was transferred to a flask and trace solvent was removed under reduced pressure,
yielding 245.2 mg (30%) of 2.7 as a pale brown solid. 1H NMR (400 MHz, D2O, δ): 2.38–2.50
(m, 4H), 2.68–2.93 (m, 10H), 3.11–3.24 (m, 7H), 3.43–4.15 (m, 18H), 4.91–4.99 (m, 1H).
1,3-di(1,4,7,10-tetraazacyclododecan-1-yl)propan-2-ol (2.8): A solution of KOH (20%
aqueous, 25 mL) and 2.7 (524.1 mg, 0.8642 mmol) was heated to 60 °C. After 72 h, the solution
was cooled to ambient temperature, filtered, and extracted with CHCl3 (3 × 25 mL). The organic
layers were combined, dried over MgSO4, filtered, and concentrated under reduced pressure,
yielding 270.9 mg (78%) of 2.8 as a white solid. 1H NMR (400 MHz, D2O, δ): 2.47–2.87 (m,
CH2, 36H), 3.73–3.81 (m, CH, 1H);
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C NMR (101 MHz, D2O/CH3CN, δ): 43.8 (CH2), 45.0

(CH2), 45.5 (CH2), 53.1 (CH2), 59.5 (CH2), 57.9 (CH); HRESIMS (m/z): [M + H]+ calcd for
C19H44N8O, 401.3716; found, 401.3707.
1,3-dibromopropan-2-yl acetate (2.12): A solution of 1,3-dibromo-2-propanol (1.0 mL,
2.2 g, 0.010 mol, 1.0 equiv), acetic anhydride (9.5 mL, 1.0 × 10 g, 0.10 mol, 10 equiv), and
anhydrous pyridine (8.1 mL, 7.9 g, 0.10 mol, 10 equiv) was stirred at ambient temperature under
Ar. A precipitate formed after 1 h. After 3 h, the reaction mixture was filtered, concentrated to ~5
mL under reduced pressure, and purified by silica gel chromatography (9:1 hexanes/ethyl
acetate) to yield 2.31 g (91%) of 2.12 as a colorless liquid. 1H NMR (400 MHz, CDCl3, δ): 2.13
(s, 3H, COOCH3), 3.60–3.61 (d, J = 5.4, 4H, CH2Br), 5.10–5.16 (quin, J = 5.4, 1H,
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CH2CHCH2); 13C NMR (101 MHz, CDCl3, δ): 21.0 (CH3), 31.56 (CH2), 170.0 (CO); TLC: Rf =
0.48 (9:1 hexanes/ethyl acetate).
{[1,3-di(DO3A-tert-butyl ester)-2-yl]oxy}benzyl ether (2.16): A mixture of 2.3 (100.0
mg, 0.1943 mmol, 2.2 equiv), 2.11 (27.2 mg, 0.088 mmol, 1.0 equiv), and K2CO3 (61.0 mg,
0.442 mmol, 5 equiv) in anhydrous acetonitrile (5 mL) under Ar was heated at 65 °C. After 72 h,
the reaction mixture was cooled to ambient temperature and filtered through Whatman 4 paper to
remove inorganic solids. The filtrate was concentrated under reduced pressure leaving a viscous
yellow residue. The residue was dissolved in CHCl3 (2 mL) and purified by silica gel
chromatography (9:1 CHCl3/MeOH) to yield 20.8 mg (21%) of 2.16 as an off-white solid. 1H
NMR (400 MHz, CDCl3, δ): 1.23–1.47 (m, CH3, 54H), 2.23–3.43 (m, 47H), 4.60–4.63 (m, 4H),
7.18–7.35 (m, phenyl CH); 13C NMR (101 MHz, CDCl3, δ): 24.1–28.4 (m, CH3), 45.9–59.9 (m,
CH2), 55.8 (CH), 82.6 (C(CH3)3), 82.9 (C(CH3)3), 126.6, 127.3, 126.4, 170.7, 172.6; TLC: Rf =
0.36 (9:1 CHCl3/MeOH).
{[1,3-di(DO3A-tert-butyl ester)-2-yl]oxy}acetyl ester (2.17): A mixture of 2.3 (1.132 g,
2.200 mmol, 2.2 equiv), 2.12 (259.9 mg, 1.000 mmol, 1.0 equiv), and K2CO3 (691.1 mg, 5.000
mmol, 5.0 equiv) in anhydrous acetonitrile (10 mL) under Ar was heated at 70 °C. After 72 h,
the reaction mixture was cooled to ambient temperature and filtered through Whatman 4 paper to
remove inorganic solids. The filtrate was concentrated under reduced pressure leaving a viscous
yellow residue. The residue was dissolved in CHCl3 (5 mL) and purified by silica gel
chromatography (stepwise gradient CHCl3 to 85:15 CHCl3/MeOH to MeOH) to yield 237.4 mg
(21%) of 2.17 as an off-white solid. 1H NMR (400 MHz, CD3CN, δ): 1.15–1.60 (m, CH3, 54H),
1.91–3.74 (m, 51H), 5.31–5.48 (m, CH, 1H);
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C NMR (101 MHz, CD3CN, δ): 22.1 (CH3),
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27.8–28.3 (m, CH3), 48.0–54.0 (m, CH2), 58.3 (CH), 56.9–58.7 (CH2), 82.8–83.2 (m), 172.2,
173.9, 174.6; TLC: Rf = 0.24 (9:1 CHCl3/MeOH).
Expected Applications
A fused-ring configuration bridging two Ln3+ ions would be advantageous from the
standpoint of generating a contrast agent for MRI with a di-Gd3+ complex because the Gd–H
vectors would be locked together, eliminating the detrimental effects of internal motion on
relaxivity. With the internal motion eliminated, the rotational correlation time of the complex
would be strictly a function of the hydrodynamic radius of the complex, which was expected to
be greater than that of monometallic complexes. This bridged, dimetallic platform may also
allow the effects of metal–metal distance on important parameters such as the electronic
relaxation times (T1e and T2e) to be probed in a bridged environment, which could then be
compared to previously reported, distance-only systems.refs A necessary feature of contrast
agents for MRI is the presence of an exchangeable water molecule bound to the Gd3+ ion.1999
caravan chem. rev

Gadolinium(III) is 9 coordinate in nearly all examples with similar ligands. As such,

I expected that each Gd3+ ion chelated by 2.1 would contain one bound water molecule.
However, as I will detail in Chapter 3, luminescence-decay measurements indicated that there
were no water molecules coordinated to the Eu3+ analog. Given this result, I did not pursue
further studies on the contrast-enhancing behavior of Gd22.1.
The alcohol bridge forced by this ligand might also provide a highly shifted,
exchangeable proton that would allow complexes with lanthanides other than Gd3+ to be used as
paramagnetic chemical exchange saturation transfer (PARACEST) agents. However, after many
PARACEST experiments in a variety of water-containing solvent systems, no suppression of the
bulk water signal was observed. A likely reason for this result is that the proton-exchange rate
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was too rapid, at the pH of my measurements, for a separate proton signal to be observed on the
NMR time-scale. A fast exchange rate should be expected for a bridging alcohol because the pKa
of the alcohol proton should be lowered by coordinating the oxygen to two Ln3+ ions. The data
presented in Chapter 3 suggested that the pKa was substantially lower than that of an unbound
alcohol, corroborating my explanation.
In addition to magnetic imaging properties, many lanthanides exhibit fluorescent and
phosphorescent behavior under irradiation from UV or visible light. The luminescence spectrum
and lifetime (or decay-rate) of a complex can be used to approximate symmetry and determine
water-coordination number, and luminescent Ln3+ complexes also offer potential use as optical
imaging probes. After finding that the Ln22.1 complexes were shielded from water, which is
often advantageous for Ln3+-based luminescent probes, I began to explore the luminescence
properties of Eu22.1. One hypothesis I developed was that the luminescence-decay rate of Eu22.1
would depend on the protonation state of the bridging alcohol. Therefore, the luminescencedecay rate could be used as a readout of pH. In Chapter 3, I describe the testing of this
hypothesis.
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CHAPTER 3: Concentration-Independent pH Detection with a Luminescent Dimetallic
Eu3+-Based Probe
Adapted with permission from Moore, J.D.; Lord, R.L; Cisneros, G.A.; Allen, M.J. J. Am. Chem.
Soc. 2012, 134, 17372–17375. Copyright 2012 American Chemical Society.
Introduction
Molecular imaging with fluorescence microscopy is a powerful tool in biochemical and
biomedical research. Organic fluorescent probes that respond to the presence of specific
molecular analytes are limited by photobleaching, broad emission bands (~100 nm), small Stokes
shifts (<20 nm), and short-lived emissions (<100 ns). Lanthanide-based probes overcome many
of the limitations associated with organic fluorophores because they offer atomic-based
emissions that do not photobleach, emit line-like bands (<20 nm bandwidth), have large Stokes
shifts, and exhibit long luminescence lifetimes (ms). Due to these advantages, many examples of
lanthanide-based probes have been reported for the detection of biologically important cations,94
anions,95 neutral species,96 proteins and peptides,97 and DNA.98 Many of these probes rely on the
ratio of two emission peaks to determine analyte concentration, but the luminescence-decay rate
of Eu3+-containing complexes should enable the determination of analyte concentration without
knowledge of probe concentration or extinction coefficient. Reports describing time-resolved
microscopy,99 luminescence-lifetime imaging,100 and phosphorescence-quenching microscopy101
demonstrate that luminescence-decay rates can be determined from microscopy and are,
therefore, a useful parameter for sensing applications. Lanthanide-based probes often exhibit low
sensitivity that can be addressed by the use of antennae or through he use of multimetallic
complexes that increase sensitivity additively.102 In targeting the multimetallic strategy, I
synthesized a new dimetallic Eu3+-containing complex, 3.1, that responds to pH over a
physiologically relevant range of 4 to 8 by a new mechanism, based on luminescence-decay
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rates, that is independent of the probe concentration and selective for only proton concentration.
To my knowledge, no system of this type has been reported to respond to pH by luminescencedecay rate.
I hypothesized that bridging two Eu3+ ions with an alcohol would decrease electron
density on the bridging oxygen and increase the acidity of the alcohol compared to an
uncoordinated alcohol. I anticipated that the acid–base equilibrium of the bridging oxygen would
result in a pH-dependent change in the luminescence-decay rate because the luminescence-decay
rate of Eu3+ increases with the number of hydroxyl oscillators coordinated to the metal ion.103 I
expected this change to be independent of the concentration of 3.1 because luminescence-decay
rate is not dependent on metal concentration. Further, I expected that this mechanism would be
selective for protons because hydroxyl oscillators have the correct vibrational energy levels to
efficiently quench Eu3+ luminescence. Here, I present the synthesis, characterization, and
spectroscopic and computational analyses of dimetallic Eu3+-containing complex 3.1.
Additionally, I propose a mechanism for the pH-dependent luminescence-decay rate supported
by our experimental and computational data.
My

complex

design

incorporates

two

Eu3+-containing

2,2',2''-(1,4,7,10-

tetraazacyclododecane-1,4,7-triyl)triacetate complexes bridged by an iso-propanol linker that is
positioned to form two ortho-fused five-membered rings containing the two metal ions. The
synthesis of 3.1 was completed in four steps (Scheme 3.1). Briefly, 1,3-dibromo-2-propanol was
converted to triethylsilyl ether 3.2, which was used to alkylate two equivalents of 1,4,7,10tetraazacyclododecane-1,4,7-tris(tert-butyl acetate) yielding the protected ligand 3.3. I found it
imperative that the alcohol be protected for the success of this alkylation. Ligand 3.4 was
obtained by global deprotection of 3.3 with trifluoroacetic acid (TFA), and Eu3+ complexation
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Scheme 3.1. Synthetic route to 3.1. Reprinted with permission from Moore, J.D.; Lord, R.L;
Cisneros, G.A.; Allen, M.J. J. Am. Chem. Soc. 2012, 134, 17372–17375. Copyright 2012
American Chemical Society.
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was achieved by addition of an aqueous solution of Eu3+ trifluoromethanesulfonate (OTf) to
ligand 3.4 at pH 6.5. Dialysis yielded dimetallic Eu3+-containing complex 3.1. A xylenol orange
test indicated that there was no unchelated Eu3+ ions present at pH 5.8 even after storing in
solution at ambient temperature for 24 h.104
Experimental Procedures
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Water was purified using a PURELAB Ultra
Mk2 water purification system (ELGA). Tri-tert-butyl-2,2',2''-(1,4,7,10-tetraazacyclododecane1,4,7-triyl)triacetate (DO3A-tert-butyl ester) was prepared according to a published procedure.92
Flash chromatography was performed using silica gel 60, 230–400 mesh (EMD
Chemicals). Analytical thin-layer chromatography (TLC) was carried out on ASTM TLC plates
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precoated with silica gel 60 F254 (250 μm layer thickness). TLC visualization was accomplished
by charring with potassium permanganate stain (3 g KMnO4, 20 g K2CO3, 5 mL 5% w/v aqueous
NaOH, 300 mL H2O) or by charring with ceric ammonium molybdate stain (4 g cerium(IV)
sulfate hydrate complex with sulfuric acid, 100 g ammonium molybdate tetrahydrate, 900 mL
H2O, 100 mL concd H2SO4).
1
13

H NMR spectra were obtained using a Varian Unity 400 (400 MHz) spectrometer, and

C NMR spectra were obtained using a Varian Unity 400 (101 MHz) spectrometer. Chemical

shifts are reported relative to residual solvent signals (CDCl3: 1H: δ 7.26, 13C: δ 77.23; H2O: 1H:
δ 4.79). 1H NMR data are assumed to be first order, and the apparent multiplicity is reported as
“t” = triplet, “q” = quartet, “quin” = quintet, and “m” = multiplet. Italicized elements are those
that are responsible for the shifts. High-resolution electrospray ionization mass spectra
(HRESIMS) were obtained using an electrospray time-of-flight high-resolution Waters
Micromass LCT Premier XE mass spectrometer.
[(1,3-Dibromopropan-2-yl)oxy]triethylsilane (3.2): To a solution of 1,3-dibromopropan2-ol (3.0 mL, 6.4 g, 0.030 mol, 1 equiv), pyridine (4.8 mL, 4.6 g, 59 mmol, 2 equiv), and
anhydrous dichloromethane (290 mL) under Ar at at 0 °C was added triethylsilyl
trifluoromethanesulfonate (12 mL, 15 g, 55 mmol) at a rate of 3 mL/h via syringe pump. The
resulting reaction mixture was allowed to warm to ambient temperature after 6 h at 0 °C. Stirring
was continued at ambient temperature for 2 h. Volatiles were removed under reduced pressure,
and the resulting residue was purified by silica gel chromatography (hexanes) to yield 9.45 g
(97%) of 3.2 as a colorless oil. 1H NMR (400 MHz, CDCl3, δ): 0.65 (q, J = 8.0 Hz, SiCH2, 6H),
0.98 (t, J = 8.0 Hz, CH3, 9H), 3.44–3.54 (m, BrCH2, 4H), 4.01 (quin, J = 5.2 Hz, CH, 1H); 13C
NMR (101 MHz, CDCl3, δ): 5.1 (CH2), 7.0 (CH3), 35.7 (CH2), 71.3 (CH); TLC: Rf = 0.35
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(hexanes). Anal. Calcd for C9H20Br2OSi: C, 32.54; H, 6.07; N, 0.00. Found: C, 32.62; H, 5.96;
N, 0.00.
{[1,3-Di(DO3A-tert-butyl ester)-2-yl]oxy}triethylsilane (3.3): A mixture of DO3A-tristert-butyl ester (10.01 g, 19.43 mmol, 2.2 equiv), 3.2 (2.93 g, 8.83 mmol, 1 equiv), and K2CO3
(6.12 g, 0.440 mol, 5 equiv) in anhydrous acetonitrile (80 mL) under Ar was heated at reflux.
The reaction mixture turned yellow–brown after 2 h and was stirred at reflux for 72 h. The
reaction mixture was cooled to ambient temperature and filtered through Whatman 4 paper to
remove inorganic solids. The filtrate was concentrated under reduced pressure leaving a viscous
yellow residue. The residue was dissolved in CHCl3 (80 mL), and the resulting organic phase
was washed with saturated aqueous NaHCO3 (3 × 80 mL). The organic layer was concentrated
under reduced pressure to ~10 mL and purified by silica gel chromatography (stepwise gradient
CHCl3 to 9:2 CHCl3/MeOH) to yield 2.00 g (20%) of 3.3 as an off-white solid. 1H NMR (400
MHz, CDCl3, δ): 0.46–0.66 (m, SiCH2, 6H), 0.77–0.97 (m, CH2CH3, 9H), 1.16–1.61 (m, CH3,
54H), 2.02–4.58 (m, 52H);

13

C NMR (101 MHz, CDCl3, δ): 5.6 (CH2), 5.7 (CH2), 5.9 (CH2),

7.0–7.3 (m, CH3), 27.8–28.5 (m, CH3), 49.5–53.0 (m, CH2), 55.7–57.4 (m, CH2), 66.2–66.9 (m,
CH), 80.0–83.2 (m), 169.1–171.1 (m), 172.7; TLC: Rf = 0.44 (9:2 CHCl3/MeOH); HRESIMS
(m/z): [M + H]+ calcd for C61H119N8O13Si, 1199.8666; found, 1199.8649.
1,3-Di[1,4,7,10-tetraazacyclododecanyl(1,4,7-triacetate)]propan-2-ol (3.4): To a solution
of 3.3 (1.58 g, 1.32 mmol, 1 equiv) in CH2Cl2 (10 mL) was added a solution of water (0.5 mL) in
trifluoroacetic acid (TFA) (10 mL). The resulting solution was stirred for 24 h. The solution was
concentrated under reduced pressure, and the resulting residue was dissolved in methanol (2 mL)
and added to diethyl ether (11 mL) in a centrifuge tube. The product precipitated as an off-white
solid and was centrifuged and washed with diethyl ether (5 × 11 mL). Solvent was removed
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under reduced pressure to yield 1.15 g (80%) of 3.4 • 2.7 TFA • 2 H2O. 1H NMR (400 MHz,
D2O, 45 °C, δ): 2.75–4.17 (m, CH2, 48H), 4.50–4.62 (m, CH, 1H); HRESIMS (m/z): [M + Na]+
calcd for C31H56N8NaO13, 771.3865; found, 771.3878; Anal. Calcd for C31H56N8O13 • 2.7
C2HF3O2 • 2 H2O: C, 40.01; H, 5.78; N, 10.25. Found: C, 39.76; H, 5.73; N, 10.58.
Sodium{1,3-bis[europium(1,4,7,10-tetraazacyclododecanyl(1,4,7-triacetate))]propan-2oxide} (Na3.1): A solution of 3.4 • 2.7 TFA • 2 H2O (103 mg, 0.0950 mmol, 1 equiv) in water
(10 mL) was adjusted to pH 6.5 with 1 M NaOH. An aqueous solution of Eu(OTf)3 (5.0 mL, 52
mM, 2.7 equiv) was added to the solution of 3.4. The pH of the solution was maintained at 6.5
with 1 M NaOH while stirring for 18 h. Upon observation of constant pH for 6 h, the pH of the
solution was adjusted to 11 with 1 M NaOH to precipitate excess europium. The solution was
filtered through a 0.2 µm syringe filter, neutralized to pH 7 with 1 M HCl, and dialyzed in 500
Da molecular weight cut-off tubing against water. The dialysate was transferred to a vial and
concentrated under reduced pressure to yield 107 mg (80%) of Na3.1 • 0.5 NaOTf • 3 H2O as a
white solid. HRESIMS (m/z): [M]– calcd for Eu2C31H49N8O13, 1043.1816; found, 1043.1830.
Anal. Calcd for Eu2C31H49N8O13Na • 0.5 CF3SO3Na • 3 H2O: C, 31.30; H, 4.58; N, 9.27. Found:
C, 31.43; H, 4.81; N, 9.04.
Determination of the q Value of 3.1
Luminescence-decay measurements were acquired using a HORIBA Jobin Yvon
Fluoromax-4 spectrofluorometer in decay by delay scan mode using the phosphorescence
lifetime setting. All decay measurements were acquired with a 395 nm excitation wavelength, a
595 nm emission wavelength, excitation and emission slit widths of 5 nm, a flash count of 100,
an initial delay of 0.01 ms, a max delay of 3 ms, and a delay increment of 0.1 ms. The natural log
plot of the intensity was plotted against time, and the slope was used as the decay rate (Figure
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3.1). The decay rates of 3.1 in H2O (pH 5.4) and D2O were used in equation 1, which was
derived by Horrocks and coworkers to calculate q.103 We accounted for quenching due to an
inner-sphere hydroxyl oscillator that we expected to be present at pH 5.4 by subtracting the term
0.45nOH, where n=1.103
equation 3.1:

Figure 3.1. Natural log plot of luminescence intensity of 3.1 in H2O (□)
and D2O (○) as a function of time. Reprinted with permission from
Moore, J.D.; Lord, R.L; Cisneros, G.A.; Allen, M.J. J. Am. Chem. Soc.
2012, 134, 17372–17375. Copyright 2012 American Chemical Society.
Luminescence-Decay Measurements and Spectra of 3.1 at Different pH Values
Buffer solutions (50 mM citrate and 50 mM phosphate) were prepared from pH 4 to 8 by
0.2 pH units for a total of 21 buffer solutions. Each sample was prepared by mixing 3.1 (18 µL,
of a 0.50 or 1.0 mM in water) with buffer (232 µL). The luminescence decay of each sample was
measured within 5 minutes of sample preparation. All decay measurements were acquired with a
395 nm excitation wavelength, a 595 nm emission wavelength, excitation and emission slit
widths of 5 nm, a flash count of 100, an initial delay of 0.01 ms, a max delay of 3 ms, and a
delay increment of 0.1 ms. The natural log plot of the intensity was plotted against time, and the
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slope was used as the decay rate. Spectra were acquired on each of the 21 samples with an
excitation wavelength of 395 nm, excitation slit width of 5 nm, and emission slit width of 1 nm
(Figure 3.2).

Figure 3.2. Natural log plots of luminescence intensity
of 3.1 in 50 mM citrate and 50 mM phosphate buffer at
pH values of 4 (red) through 8 (pink) by 0.2 pH units.
Reprinted with permission from Moore, J.D.; Lord, R.L;
Cisneros, G.A.; Allen, M.J. J. Am. Chem. Soc. 2012,
134, 17372–17375. Copyright 2012 American Chemical
Society.
Results and Discussion
Water Coordination Analysis
To assess the coordination environment of the Eu3+ ions, the number of water molecules
coordinated to the Eu3+ ion, q, was determined using the method developed by Horrocks and
coworkers.103 Complex 3.1 was found to have a q value of 0 in the absence of buffer (pH 5.4),
suggesting that no water was bound to the Eu3+ ions. When I considered possible structures to
satisfy this data, I was unable to construct a structure lacking a bridge between Eu3+ ions that
contained no water molecules bound to the Eu3+ ions. This q data indicated that the Eu3+ ions are
bridged by an alcohol donor from the ligand. Because coordinated OH oscillators influence the
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luminescence-decay rate of Eu3+ ions, I hypothesized that there would be a decrease in the
luminescence-decay rate of 3.1 with increasing pH above 5.4 due to deprotonation of the
bridging alcohol.
To test this hypothesis, I prepared 0.5 mM solutions of 3.1 in a series of buffers from pH
4.0 to 8.0 in increments of 0.2 pH units. The luminescence-decay rate of each solution was
determined and plotted against pH values (Figure 3.3). I confirmed that the pH response is
independent of the concentration of 3.1 by repeating the luminescence-decay rate measurements
with
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Figure 3.3. Luminescence-decay rate of 0.5
(♦) and 1.0 mM (□) 3.1 as a function of pH
(50 mM citrate, 50 mM phosphate, λex = 395
nm, λem = 595 nm). Reprinted with
permission from Moore, J.D.; Lord, R.L;
Cisneros, G.A.; Allen, M.J. J. Am. Chem.
Soc. 2012, 134, 17372–17375. Copyright
2012 American Chemical Society.

of diseased tissue.105
Optimized Structure Analysis
Structures of H3.1 and 3.1– were optimized with Gaussian 09 at the PBE0/SDDall level
(small core for all atoms) using the default convergence criteria.106 The optimized structures
suggest that the alcohol bridges the Eu3+ ions and that two carboxylate oxygens are also bridging
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(Figure 3.4). This tri-bridged structure is consistent with a 9-coordinate Eu3+ environment that is
saturated by the ligand and corroborates the luminescence-decay data that indicate the absence of
water molecules bound to Eu3+. Interestingly, to obtain a suitable initial guess for the
optimization, it was necessary to include the two bridging carboxylates. To achieve this, the

Figure 3.4. Optimized structures of 3.1– (left) and H3.1 (right): Eu = pink, C = cyan, N =
blue, O = red, and H = white. Non-exchangeable hydrogen atoms are omitted for clarity.
Reprinted with permission from Moore, J.D.; Lord, R.L; Cisneros, G.A.; Allen, M.J. J. Am.
Chem. Soc. 2012, 134, 17372–17375. Copyright 2012 American Chemical Society.
orientation of the carboxylate arms on the two chelates had to be in opposite conformations from
each other (∆ vs Λ) to minimize the bridged structure. Further, the steric constraints of the ligand
prevent a bridge as small as alkoxide without two bridging carboxylates. These structures
corroborate both the exceptionally long luminescence lifetime at higher pH values and the
luminescence quenching that results from lowering pH.
Emission Spectra
To further elucidate the mechanism of the pH response, I compared the emission spectra
of 3.1 at different pH values (Figure 3.5 and Appendix B, Figure B.2). At pH 4.4, I observed
that the multiplicity of the ∆J = 1 manifold (centered at 592 nm) is at the maximum of three
peaks. This high multiplicity indicates that the symmetry around the Eu3+ ions is low. However,

52
the spectrum would indicate that the symmetry of the left and right chelates is similar because I
do not observe greater than 2J+1 peaks for any manifold in the spectrum. Surprisingly, the
spectrum of 3.1 at pH 7.4 contains four peaks in the ∆J = 1 manifold and two major peaks in the
∆J = 2 manifold. The source of these additional peaks at high pH is not immediately obvious.
One explanation that is consistent with all other data is that the loss of the intramolecular
hydrogen bond at high pH values increases the flexibility of the ligand, resulting in a change in
conformation about one or both of the Eu3+ ions. Previous studies of similar monometallic Eu3+
complexes by Horrocks and coworkers demonstrated that interconverting isomers can be
observed by luminescence spectroscopy.107

Figure 3.5. Comparison of emission spectra of 3.1 at pH 4.4 (solid
line) and pH 7.4 (dashed line) (0.5 mM 3.1, 50 mM citrate, 50 mM
phosphate, λex = 395 nm). Arrows point to peaks that may result
from a second Eu3+ environment. Reprinted with permission from
Moore, J.D.; Lord, R.L; Cisneros, G.A.; Allen, M.J. J. Am. Chem.
Soc. 2012, 134, 17372–17375. Copyright 2012 American
Chemical Society.
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Summary and Conclusions
The spectroscopic and computational data suggest a novel mechanism of pH response
wherein protonation of the bridging alkoxide under acidic conditions introduces a hydroxyl
oscillator in the Eu3+ coordination sphere (Figure 3.6). The inner-sphere hydroxyl oscillator
quenches the Eu3+ excited state resulting in a faster luminescence-decay rate. Further, because
coordination of other cations to the alkoxide will not produce oscillators with the proper energy
to quench the Eu3+ emission, I expect that this system will specifically respond to proton
concentration. Moreover, this process is reversible such that continuous monitoring of pH is
possible. To my knowledge, no other system of this kind has been reported to respond to pH by
luminescence-decay rate.

Figure 3.6. Proposed mechanism for the response of 3.1 to changes in pH. At high pH (top),
the lack of OH oscillators leads to long-lived luminescence (long wavy arrows, λem). At low
pH (bottom), the bridging OH oscillator quenches the Eu3+ excited state leading to rapid
luminescence decay (short wavy arrows, λem). Reprinted with permission from Moore, J.D.;
Lord, R.L; Cisneros, G.A.; Allen, M.J. J. Am. Chem. Soc. 2012, 134, 17372–17375.
Copyright 2012 American Chemical Society.
I have demonstrated a concentration-independent luminescence response to pH achieved
through the protic equilibrium of an alkoxide in 3.1. My characterization indicates that the Eu3+
ions have no coordinated water molecules resulting in relatively slow luminescence-decay rates,
especially at pH values above 7. The absence of coordinated water molecules makes this system
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less sensitive to changes in the composition of the surrounding media relative to systems that
contain coordinated water molecules. Spectral changes with pH are indicative of a change in the
coordination sphere in agreement with my proposed mechanism. Computationally optimized
structures also are consistent with my experimental observations. Complex 3.1 represents a
unique system using a new mechanism by which pH can be detected and offers a useful method
for concentration-independent, non-invasive, continuous pH imaging. I expect that this research
is a step toward powerful tools for biomedical and biochemical research because pH is often an
indicator of disease.
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CHAPTER 4: Tb3+ to Eu3+ Energy Transfer in a Heterodimetallic Complex
Introduction
Lanthanide–lanthanide (Ln–Ln) energy transfer is a well-known phenomenon in
extended solids,108 glasses,109 concentrated solution,110 clusters,111 and aggregate homo- and
heterometallic lanthanide-containing

systems.112 However, to date, examples of this

phenomenon have been reported for only five discrete molecular complexes in aqueous medium
(Figure 4.1). The first example was reported by Faulkner and Pope in 2003 for Tb3+/Yb3+
heterotrimetallic complex 4.1.113 The second example was reported in 2006 by Tremblay and
Sames for a Tb3+/Eu3+ complex 4.2.114 The third and fourth examples were reported in 2011 by
Andolina and Morrow for Eu3+/Nd3+ heterodimetallic complexes 4.3 and 4.4.83 The fifth example
was reported by Nonat and coworkers in 2012 for a homodimetallic Eu3+ complex 4.5.115

Figure 4.1. Previously reported multimetallic complexes that exhibit Ln–Ln energy
transfer.83, 113–115
Three requirements must be satisfied for spontaneous energy transfer to occur: (1) a
donor ion must absorb excitation energy into an excited state; (2) an acceptor ion must have an
excited state slightly lower in energy than the donor excited state; and (3) the donor and acceptor
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ions must be physically close enough to facilitate a positive overlap integral between the excited
states. Complex 4.1 contains Tb3+ as the donor and Yb3+ as the acceptor; 4.2 contains Tb3+ as the
donor and Eu3+ as the acceptor; and 4.3 and 4.4 contain Eu3+ as the donor and Nd3+ as the
acceptor. Unlike complexes 4.1–4.4, complex 4.5 contains two Eu3+ ions, one serving as the
donor and the other as the acceptor. Table 4.1 outlines the energy levels of the donor and
acceptor ions in complexes 4.1–4.4 and the absorption and emission wavelengths expected
during energy transfer. Based on the values in Table 4.1, the energy state requirements (1) and
(2) are satisfied with the metal pairs in Figure 4.1. Further, the distance requirement is likely
satisfied in these complexes. Without crystallographic evidence for the donor–acceptor distance,
we can only assume that the metal ions are close enough to provide a pathway for energy
transfer; however, data consistent with energy transfer could be considered evidence of a metal–
metal distance (d) of less than 10 Å.116 Such data is has been used to make molecular
measurements in proteins and other complex molecules.117 These studies assume that energy
transfer occurs via the dipole–dipole Förster mechanism, in which the efficiency of energy
transfer is proportional to d–6 and can be effective up to 10 Å.116
Table 4.1. Summary of energy states involved in energy transfer for lanthanides used in 4.1–4.4.
Donor Donor State
λex* Acceptor Acceptor State
3+
–1
State
Energy (cm ) (nm) State
Energy (cm–1)
λem* (nm)
Ln
Tb3+ 5D4
20,408
490 ––––
–––––
––––––––––––––––––––
3+ 5
5
Eu
D0
17,241
580 D0
17,241
580, 595, 615, 650, 720
Nd3+ –––
–––––
––– 4F3/2
11,111
900, 1060, 1350
–––––
––– 2F3/2
10,204
980
Yb3+ –––
*wavelength values can vary ±5 nm
The method used to demonstrate energy transfer in the studies of 4.1 and 4.3–4.5 was a
comparison of the luminescence-decay rate of the donor ion in the absence and presence of the
acceptor.83, 113, 115 In this approach, the donor is treated as being quenched by the acceptor. A
faster decay rate in the presence of the acceptor suggests Ln–Ln energy transfer. However, Eu3+
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and Tb3+ are also quenched by CH, NH, and OH oscillators. This fact limits the interpretation of
luminescence-decay rate differences, particularly when the molecular structure is changed by
removing the acceptor ion. An orthogonal technique to observe energy transfer is to acquire
steady state excitation and emission spectra of the complex. While the decay data presented in
studies of 4.1 and 4.3–4.5 indicate that energy transfer occurs in these systems, the authors do
not report excitation and emission spectra associated with such a process. Emission spectra for
4.2 were reported and show simultaneous emission from Tb3+ and Eu3+; however, the spectra
were acquired with ligand-sensitized excitation. No evidence of Eu3+ emission with direct Tb3+
excitation or Tb3+ luminescence-decay data was presented.114 Ultimately, for Ln–Ln energy
transfer to prove practically useful, the energy transfer process needs to be efficient enough to
produce acceptor-based emission spectra from donor-based excitation. To satisfactorily
characterize the presence of Ln–Ln energy transfer, I propose that both steady state spectra and
luminescence-decay data must be reported to completely identify the energy transfer process.
To this end, I synthesized Tb3+- and Eu3+-containing heterodimetallic complex 4.6
(Figure 4.2). My previous work, described in Chapter 3, indicated that the structure of the
homodimetallic Eu3+ analog was bridged by three oxygen atoms (Figures 3.4 and 3.6). Due to
the similar ionic radii of Tb3+ and Eu3+, I expected the structure of 4.6 to be similarly bridged.
Using Tb3+ and Eu3+, I hypothesized that energy transfer from Tb3+ to Eu3+ would empirically
confirm the optimized structure and provide a platform for tuning the excitation, emission, and
lifetime properties of lanthanide-based probes.
A discrete molecule exhibiting efficient Ln–Ln energy transfer could be useful for
fundamental studies of energy transfer mechanisms as well as for fluorescence imaging. Many
lanthanide-based luminescent probes have been developed because of the narrow absorption and
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emission bands of these ions.116 Additionally, lanthanide ions exhibit microsecond to millisecond
luminescence lifetimes, allowing typically weak lanthanide-based emission bands to be observed
after background organic-based fluorescence decays.116 Further, Nd3+, Sm3+, Ho3+, Er3+, and
Yb3+ emit in the near-IR region, which may allow background fluorescence to be avoided
completely and may also provide probes that can be observed through opaque tissue. Introducing
a system wherein the excitation, emission, and lifetime properties can be selected simply by
choosing the metal ions to chelate in a ligand may offer new capabilities to biological and
medical imaging, providing a boon to research and diagnostic medicine.

Figure 4.2. Dimetallic complexes reported in this chapter.
Experimental Procedures
General Procedures
Commercially available chemicals were of reagent-grade purity or better and were used
without further purification unless otherwise noted. Water was purified using a PURELAB Ultra
Mk2 water purification system (ELGA). Preparation of 1,3-di[1,4,7,10-tetraazacyclododecanyl(1,4,7-triacetate)]propan-2-ol, 3.4, was carried out according to my published procedure.Moore,
JACS 2012

Purification of metal complexes was carried out using reverse-phase high-performance

liquid chromatography (HPLC) with a binary gradient (H2O/CH3CN) using two Shimadzu
Prominence LC20AT HPLC pumps, SIL-20AHT autosampler, RF10AXL fluorescence detector
(λex = 394 nm, λem = 616 nm for 4.7 and λex = 228 nm, λem = 545 nm for 4.8) fitted with a
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Pinnacle PPFP column (10 mm × 250 mm, Restek). Centrifugation was carried out using a
Fisher Scientific Centric centrifuge (Model 255) operated at speed setting 8 for 5 minutes. All
samples were filtered through Millex-LG hydrophilic PTFE syringe filters (4 mm or 25 mm).
Purity and identification of HPLC-purified compounds was determined by HPLCcoupled electrospray ionization mass spectrometry (ESIMS) using a Pinnacle PPFP column (4
mm × 250 mm, Restek) and an electrospray Shimadzu LCMS2010EV spectrometer. Highresolution electrospray ionization mass spectra (HRESIMS) were obtained using an electrospray
time-of-flight high-resolution Waters Micromass LCT Premier XE mass spectrometer and were
acquired without use of a column.
Syntheses of Metal Complexes
Ammonium{1,3-bis[europium-(1,4,7,10-tetraazacyclododecanyl-(1,4,7triacetate))]propan-2-oxide} (NH44.7): A solution of 1,3-di[1,4,7,10-tetraazacyclododecanyl(1,4,7-triacetate)]propan-2-ol (4.9) (1.17 mL , 57.07 mM, 0.0668 mmol, 1 equiv) was added to a
flask, and the pH of the solution was adjusted to 6.5 with NH4OH (5% aqueous solution). To the
resulting solution of 4.9 was added an aqueous solution of europium triflate (49.58 mM, 4.00
mL, 0.200 mmol, 3 equiv). The resulting solution was stirred at ambient temperature for 12 h
while the pH was maintained at 6.5 with NH4OH (5% aqueous solution). After 12 h, the pH was
raised to 10 with NH4OH (1 mL, 30% aqueous solution) to precipitate excess europium as
insoluble hydroxide. After stirring for 12 h, the resulting mixture was centrifuged and the
supernatant was separated. The solid was washed with NH4OH (5 mL, 5% aqueous solution); the
mixture was centrifuged; and the supernatant was removed. This washing procedure was
repeated three times. The combined supernatants were filtered through a 0.2 μm syringe filter to
remove any remaining Eu(OH)3. The solution was concentrated under reduced pressure. HPLC-
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MS analysis indicated that the solution contained both 5- and 6-arm metal complexes (Figures
4.3a and 4.3b). Therefore, the desired 6-arm product was purified by collecting the HPLC eluent
at 14.5 minutes (4 mL/min, 5 to 15% CH3CN/H2O over 4 min). The combined fractions were
concentrated, and the solvent was removed under reduced pressure to yield 47.6 mg (64%) of
NH44.7. Purity was confirmed by HPLC-MS analysis (4 mL/min, 5 to 15% CH3CN/H2O over 4
min) (Figure 4.4). HRESIMS (m/z): [M]– calcd for Eu2C31H49N8O13, 1043.1816; found,
1043.1830.

Figure 4.3a. (a) HPLC chromatogram of 4.7 prior to HPLC purification (λex = 394 nm, λem =
616 nm). (b) Extracted mass spectrum at 14.620 min retention time. (c) Extracted mass
spectrum at 15.700 min retention time.
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Figure 4.3b. (d) Extracted mass spectrum at 17.410 min retention time. Inset illustrates the 5arm species that corresponded to the observed mass peaks. (e) Extracted mass spectrum at
18.745 min retention time. Inset illustrates the 5-arm species that corresponded to the
observed mass peaks. (f) Extracted mass spectrum at 21.415 min retention time. Inset
illustrates the monometallated Eu3+-containing 6-arm species that corresponded to the
observed mass peaks.
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Figure 4.4. (Top) HPLC chromatogram of 4.7 (λex = 394 nm, λem = 616 nm). (Bottom)
Extracted mass spectrum averaged over 13.945–15.055 min retention time.
Ammonium{1,3-bis[terbium-(1,4,7,10-tetraazacyclododecanyl-(1,4,7-triacetate))]propan2-oxide} (NH44.8): An aliquot of 4.9 (57.07 mM, 2.30 mL, 0.131 mmol, 1 equiv) was added to a
flask, and the pH of the solution was adjusted to 6.5 with NH4OH (5% aqueous solution). To the
solution of 4.9 was added a solution of terbium triflate (183.9 mg, 0.3083 mmol, 2.3 equiv) in
water (1 mL). The resulting solution was stirred at ambient temperature for 12 h while the pH
was maintained at 6.5 with NH4OH (5% aqueous solution). After 12 h, the pH was raised to 10
with NH4OH (1 mL, 30% aqueous solution) to precipitate excess terbium as insoluble
hydroxides. After stirring for 12 h, the resulting mixture was centrifuged, and the supernatant
was separated. The solid was washed with NH4OH (5 mL, 5% aqueous solution); the mixture
was centrifuged; and the supernatant was removed. This washing procedure was repeated three
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times. The combined supernatants were filtered through a 0.2 μm syringe filter to remove any
remaining Tb(OH)3. The solution was concentrated under reduced pressure. HPLC-MS analysis
indicated that the solution contained both 5- and 6-arm metal complexes. Therefore, the desired
6-arm product was purified by collecting the HPLC eluent at 4.3 minutes (4 mL/min, 10%
CH3CN/H2O). The combined fractions were concentrated, and the solvent was removed under
reduced pressure to yield 27.2 mg (18%) of NH44.7. Purity was confirmed by HPLC-MS
analysis (1 mL/min, 10% CH3CN/H2O) (Figure 4.5). HRESIMS (m/z): [M+H]+ calcd for
Tb2C31H49N8O13, 1061.2083; found, 1061.2072.
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Figure 4.5. (Top) HPLC chromatogram of 4.8 (λex = 228 nm, λem = 545 nm). (Bottom)
Extracted mass spectrum averaged over 3.805–5.170 min retention time.
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Ammonium{1-[europium-(1,4,7,10-tetraazacyclododecanyl-(1,4,7-triacetate)),

3-

[terbium-(1,4,7,10-tetraazacyclododecanyl-(1,4,7-triacetate))]propan-2-oxide} (4.6): A solution
of 4.9 in water (1.00 mL, 57.07 mM, 0.057 mmol, 1 equiv) was added to a flask, and the pH of
the solution was adjusted to 6.5 with NH4OH (5% aqueous solution). To the solution of 4.9 was
added a solution of europium triflate (1.15 mL, 49.58 mM, 0.057 mmol, 1 equiv). The resulting
solution was stirred at ambient temperature for 10 min while the pH was maintained at 6.5 with
NH4OH (5% aqueous solution). To the resulting solution was added a solution of terbium triflate
(1.58 mL, 36.04 mM, 0.057 mmol, 1 equiv). The resulting solution was stirred at ambient
temperature for 12 h while the pH was maintained at 6.5 with NH4OH (5% aqueous solution).
After 12 h, the pH was raised to 10 with NH4OH (1 mL, 30% aqueous solution) to precipitate
excess europium and terbium as insoluble hydroxides. After stirring for 12 h, the resulting
mixture was centrifuged and the supernatant was separated. The solid was washed with NH4OH
(5 mL, 5% aqueous solution); the mixture was centrifuged; and the supernatant was removed.
This washing procedure was repeated three times. The combined supernatants were filtered
through a 0.2 μm syringe filter to remove any remaining Eu(OH)3 and Tb(OH)3. The solution
was concentrated under reduced pressure. HPLC-MS analysis indicated that the solution
contained both 5- and 6-arm metal complexes including complexes 4.6 and 4.7. Complexes 4.6
and 4.7 could not be separated, likely due to structural similarities. Therefore, the 6-arm
products, 4.6 and 4.7, were isolated as an inseparable mixture by collecting the HPLC eluent at
13.9 minutes (4 mL/min, 5 to 15% CH3CN/H2O over 4 min). The combined fractions were
concentrated and the solvent was removed under reduced pressure to yield 28.34 mg of a mixture
of NH44.6 and NH44.7 (Figure 4.6). No evidence of 4.8 was observed, likely due to the order of
addition of the metals.
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Figure 4.6. (Top) HPLC chromatogram of mixture of 4.6 and 4.7 (λex = 228 nm, λem = 545
nm). (Middle) Extracted mass spectrum at 13.435 min retention time. (Bottom) Extracted
mass spectrum at 14.005 min retention time.
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Steady State Luminescence Spectra and Luminescence-Decay Rate Measurements
Luminescence excitation and emission spectra were acquired using a HORIBA Jobin
Yvon Fluoromax-4 spectrofluorometer equipped with a 400 W xenon lamp in fluorescence
mode. Excitation spectra were acquired by scaning from 200 to 540 nm excitation wavelength
(increment = 1 nm, excitation slit width = 1 nm, emission slit width = 5 nm). Excitation spectra
for all complexes were acquired at 545 and 612 nm emission wavelengths, corresponding to the
emission maxima of Tb3+ and Eu3+, respectively. Emission spectra were acquired with 394 and
487 nm excitation wavelengths, corresponding to the excitation maxima specific to Eu3+ and
Tb3+, respectively. Emission spectra were acquired by scanning from 430 to 725 nm excitation
wavelength (increment = 1 nm, excitation slit width = 5 nm, emission slit width = 1 nm).
Samples of 4.6, 4.7, and 4.8 were prepared by dissolving the solids in water (1 mL) and
transferring a 250 μL aliquot of the resulting solutions to a 2 mm × 2 mm × 32 mm quartz
cuvette. A mixture of homodimetallic complexes 4.7 and 4.8 was prepared by mixing 125 μL
aliquots of the individual mixtures prepared above. The pH of all samples was approximately 7.5
as measured with pH paper.
Results and Discussion
Spectral Assignment of Tb3+ and Eu3+ Complexes
Luminescence emissions from Tb3+ originate from depopulation of the 5D4 energy level
to the 7F manifold (Figure 4.7). The 5Dj and 7Fj levels of Tb3+ are almost exclusively composed
of 4f8 orbitals that are shielded from bonding and crystal field perturbations and require minimal
nuclear reorganization energy upon excitation, resulting in minimal variation in emission
wavelengths (<10 nm) and relative intensities of each transition, regardless of coordination
environment. Therefore, Tb3+ emission spectra are predictable, and commonly observed
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Figure 4.7. Energy level diagram of Tb3+ (top left) and Eu3+ (top right) illustrating transitions
involved in excitation and emission pathways and corresponding excitation and emission
wavelengths. Representative emission spectra of Tb3+ (bottom left) and Eu3+ (bottom right).
Peak assignments correspond to the j-value of the final 7Fj state. Position of energy levels
based on data reported in references 116 and 118.
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transitions at 490, 545, 590, and 620 nm are reliably assigned to depopulation of the 5D4 state to
the 7Fj manifold, where j = 6, 5, 4, and 3, respectively (Figure 4.7).116,

118

The 5D4 → 7Fj

transitions almost always appear with intensity decreasing in order of j = 5 > 6 > 4 > 3 (Figure
4.7).
All modes of Tb3+ excitation ultimately result in population of and emission from the 5D4
level. Therefore, excitation spectra are typically acquired by scanning excitation wavelength and
monitoring the emission intensity of the 5D4 to 7F5 transition at 545 nm because it provides the
highest sensitivity. The 5D4 level of Tb3+ can be populated through multiple pathways including
indirect and direct excitation of Tb3+. Indirect excitation will not be discussed here because it
does not occur in molecules such as Tb2L, 4.6, which lack donor fluorophores. Direct excitation
of Tb3+ can be achieved by stimulation of transitions from 7F6 to 7Dj, 9D2, and 5D4 levels using
225–275, 280–340, or 490 nm radiation, respectively (Figure 4.7). The 7D and 9D are composed
of the 4f75d1 orbitals that are more strongly affected by bonding interactions than the 4f8 orbitals.
As a result, the nuclear reorganization energy is greater for transitions to the 7D and 9D levels
than the 5D4 level, resulting in broad transitions in the UV range of the excitation spectra,
denoted by the wide range of wavelengths for these transitions (Figure 4.7). Non-rediative decay
from the 7D and 9D states results in population of the 5D4 level. The excitation of the 7F6 → 5D4
transition is inefficient, resulting in weak emission, but appears consistently between 485 and
495 nm, making it a useful signature for Tb3+ excitation.
Luminescence emissions from Eu3+ originate from depopulation of the 5D0 energy level
to the 7F manifold. Similarly to Tb3+, the 5Dj and 7Fj levels of Eu3+ are almost exclusively
composed of 4f8 orbitals that are shielded from bonding and crystal field perturbations and
require minimal nuclear reorganization energy upon excitation, resulting in minimal variation in
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emission wavelengths (<20 nm) and relative intensities of each transition, regardless of
coordination environment. Therefore, Eu3+ emission spectra are predictable, and commonly
observed transitions at 580, 594, 615, 650, and 700 nm are reliably assigned to depopulation of
the 5D0 state to the 7Fj manifold, where j = 0, 1, 2, 3, and 4, respectively (Figure 4.7).116, 118 For
complexed Eu3+, the 5D4 → 7Fj transitions almost always appear with intensity decreasing in
order of j = 2 > 1 > 4 > 3 ≈ 0 (Figure 4.7).
Excitation spectra of Eu3+ are acquired by scanning excitation wavelength and
monitoring the emission intensity of the 5D0 → 7F2 transition at 615 nm because it provides the
highest sensitivity. The 5D0 level of Eu3+ can be populated through multiple pathways including
direct and indirect excitation of Eu3+. Unlike Tb3+ excitation, direct excitation of Eu3+ through 7Fj
→ 5D0 transitions is inefficient and is not practically useful without a laser excitation source.
Direct excitation of Eu3+ is achieved most efficiently by stimulation of the transition from 7F0 to
5

L6 (Figure 4.7). Due to the minimal impact of nuclear reorganization on the 7F0 → 5L6

transition, the excitation wavelength appears consistently at 395 ± 5 nm, making it a useful
signature for Eu3+ excitation. Indirect excitation of Eu3+ can be achieved via non-radiative energy
transfer from a higher-energy, donor-localized excited state to the 5D0 level. Therefore, energy
transfer is indicated if the Eu3+ emission fingerprint results from excitation of transitions not
associated with Eu3+. Importantly, the density of lanthanide energy levels increases dramatically
above 30,000 cm–1 (below 333 nm), and UV irradiation of samples containing Tb3+ and Eu3+
may result in simultaneous excitation.118 Given this ambiguity, energy transfer between these and
other lanthanides must be studied using lower energy radiation, where specific excitation of
unique Tb3+ or Eu3+ transitions is reliable. This strategy was used for the acquisition of excitation
and emission spectra of 4.6, 4.7, and 4.8, discussed in the following sections.
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Analysis of Steady State Excitation Spectra
An excitation spectrum of Eu2L, 4.7, was generated by recording the emission intensity
of the 5D0 → 7F2 transition of Eu3+ at 612 nm and scanning excitation wavelength. The resulting
excitation spectrum was typical of Eu3+-containing complexes and displayed a 394 nm excitation
maximum, corresponding to the 7F0 → 5L6 transition of Eu3+ (Figure 4.8). Importantly, an
excitation peak at 487 nm was not observed, indicating that there were no Eu3+-based transitions
that overlap the Tb3+-based 5D4 → 7F6 transition at 487 nm. Therefore, any excitation peaks at
487 nm in the Tb2L- or TbEuL-containing systems were likely to originate from Tb3+ excitation.

Figure 4.8. Steady state excitation spectra monitoring at 612 nm emission wavelength.
Spectra are normalized to the most intense peak. Inset is zoomed on the y-axis only. Energy
levels involved in the transitions are indicated above the spectrum with the corresponding ion.
Arrow indicates Tb3+-specific excitation at a Eu3+ emission wavelength.
A second excitation spectrum of Eu2L, 4.7, was acquired by recording the emission
intensity of the 5D4 → 7F5 transition of Tb3+ at 545 nm (Figure 4.9). As expected for 4.7, which
contained no Tb3+, no excitation peaks were observed while recording the emission intensity at
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545 nm, confirming that Eu3+-based emission from 4.7 would not coincide with Tb3+-based
emission in the 545 nm range with any excitation wavelength (Figure 4.9).

Figure 4.9. Steady state excitation spectra monitoring at 545 nm emission wavelength.
Spectra are normalized to the second order scattering peak designated by the asterisk. Inset is
zoomed on the y-axis only. Energy levels involved in the transitions are indicated above the
spectrum with the corresponding ion.
An excitation spectrum of Tb2L, 4.8, was generated by recording the emission intensity
of the 5D4 → 7F5 transition of Tb3+ at 545 nm and scanning excitation wavelength. The resulting
excitation spectrum displayed broad excitation maxima at 252 and 295 nm, corresponding to
Tb3+ transitions from the 7F0 to 7D and 9D states, respectively (Figure 4.9). Importantly, a weak
excitation peak at 487 nm was observed, corresponding to the Tb3+-based 5D4 → 7F6 transition at
the expected wavelength. The presence of an excitation peak at 487 nm in the spectrum of Tb2L,
4.8, combined with the absence of a peak at 487 nm in the excitation spectrum of Eu2L, 4.7,
confirmed that an excitation peak at 487 nm in the excitation spectrum of TbEuL, 4.6, originated
from Tb3+ excitation.
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A second excitation spectrum of Tb2L, 4.8, was acquired by recording the emission
intensity of the 5D0 →7F2 transition of Eu3+ at 612 nm (Figure 4.8). As expected for 4.8, which
contained no Eu3+, no excitation peaks were observed while recording the emission intensity at
612 nm, confirming that Tb3+-based emission from 4.8 would not coincide with Eu3+-based
emission in the 612 nm range with any excitation wavelength (Figure 4.8).
Because TbEuL, 4.6, could not be isolated from Eu2L, 4.7, excitation spectra were
acquired using a sample containing both 4.6 and 4.7, which I will henceforth refer to as 4.6. An
excitation spectrum of TbEuL, 4.6, was generated by recording the emission intensity of the 5D0
→ 7F0 transition of Eu3+ at 612 nm and scanning excitation wavelength (Figure 4.8). The
resulting excitation spectrum was similar to that of Eu2L, 4.7, and displayed an excitation
maximum at 394 nm, consistent with the Eu3+ transition from 7F0 to 5L6 (Figure 4.8).
Importantly, a weak excitation peak at 487 nm was also observed. The presence of an excitation
peak corresponding to the Tb3+-based 7F6 → 5D4 transition at 487 nm while monitoring the
emission from the Eu3+-based the 5D0 → 7F0 transition at 612 nm indicated that energy transfer
was occurring from the Tb3+-based 5D4 level to the Eu3+-based 5D0 level.
A second excitation spectrum of TbEuL, 4.6, was acquired by recording the emission
intensity of the 5D4 →7F5 transition of Tb3+ at 545 nm (Figure 4.9). Peaks corresponding to the
7

F6 to 7D and 9D states at 252 and 295 nm were absent, and the peak corresponding to the 7F6 to

5

D4 transition at 487 nm was substantially weaker in the spectrum of TbEuL, 4.6, than in the

spectrum of Tb2L, 4.8. The concentration of Tb3+ in the sample of 4.6 was lower than in 4.8 and
the absence of peaks at 252 and 295 nm might be the result of low concentration. However, the
ratio between the peaks at 252, 295, and 487 nm is not expected to differ dramatically between
4.6 and 4.8; and, peak at 487 nm was observed in the spectrum of 4.6, suggesting that the peaks
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at 252 and 295 nm are absent due to a quenching pathway only present in TbEuL, 4.6. Given the
increased density of energy levels at energies above 30,000 cm–1 (wavelengths below 333 nm)
for both Tb3+ and Eu3+, energy transfer between Tb3+-based 7D and 9D states and Eu3+-based high
energy excited states might be possible. However, the density of states at high energy prevents
the study of energy transfer at high energy due to ambiguous excitation. Therefore, emission
spectra were only recorded using excitation wavelengths unique to Eu3+ or Tb3+, at 394 nm or
487 nm, respectively. Based on the excitation spectra of 4.6, 4.7, and 4.8, I hypothesized that
Tb3+-centered excitation would result in Eu3+-based emission, which would confirm the
occurrence of energy transfer from Tb3+ to Eu3+. The emission spectra discussed in the following
section were used to test this hypothesis.
Analysis of Steady State Emission Spectra
The emission spectrum of Eu2L, 4.7, was similar to those previously reported with 394
nm excitation radiation and displayed the expected Eu3+-based transitions at 580, 592, 616, 653,
682, and 700 nm (Figure 4.10).93 The presence of four transitions in the 5D0 → 7F1 manifold
centered at 592 nm (Figure 4.10) suggested that there was more than one Eu3+ environment
present in 4.7 because a maximum of three transitions can occur from a single Eu3+ environment.
However, the presence of only one principle transition at 616 nm (Figure 4.10) in the 5D0 → 7F2
manifold indicated that the symmetry of the two Eu3+ ions was similar. When 4.7 was irradiated
with 487 nm radiation, specific to excitation of Tb3+, no emission was observed, as was expected
for a complex containing only Eu3+ (Figure 4.11).
The emission spectrum of Tb2L, 4.8, with 394 nm excitation radiation displayed no
emission peaks, consistent with the expected inability of Tb3+ to absorb 394 nm radiation
(Figure 4.10). The emission spectrum of Tb2L with 487 nm excitation radiation was typical of
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Figure 4.10. Steady state emission spectra (λex = 394 nm). Spectra are normalized to the most
intense peak. Assignments are indicated above the spectra with the corresponding ion.

Figure 4.11. Steady state emission spectra (λex = 487 nm). Spectra are normalized to the most
intense peak. Assignments are indicated above the spectra with the corresponding ion.
Tb3+-containing complexes, with transitions at 545, 586, and 621 nm, corresponding to
transitions from the 5D4 state to the 7F5, 7F4, and 7F3 states, respectively (Figure 4.11). Structural
information cannot be derived from the Tb3+ emission spectrum because the observed transitions
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are not sensitive to Tb3+ symmetry.116 However, the emission pattern indicated that the emission
of Tb3+ can be stimulated by direct excitation of the 7F6 → 5D4 transition at 487 nm.
Because TbEuL, 4.6, could not be isolated from Eu2L, 4.7, emission spectra were
acquired using a sample a sample containing both 4.6 and 4.7. I assigned any transitions that did
not appear in the spectra of pure 4.7 to emission from 4.6. Irradiation of the sample containing
4.6 and 4.7 with 394 nm radiation resulted in an emission spectrum with three notable
differences from the sample of pure 4.7: (1) the 5D0 → 7F0 transition at 579 nm is slightly redshifted from the 4.7 spectrum; (2) the ratio between the hyperfine transitions at 586 and 592 nm
in the 5D0 → 7F1 manifold increased compared to the spectrum of 4.7; and (3) an intense
transition in the 5D0 → 7F2 manifold appeared at 612 nm in addition to the 616 nm transition
observed in the spectrum of 4.7. All three of these observations imply the presence a Eu3+containing species with different symmetry than the Eu3+ ions in 4.7. Based on HPLC-MS data, I
expected that both 4.6 and 4.7 would be present in the sample. I assigned the peaks that appeared
in the spectrum of both 4.7 and the mixture of 4.6 and 4.7 to Eu2L, 4.7. I assigned the remaining
transitions at 586 and 612 nm to 4.6 and assumed that 4.6 also contributed transitions to all other
Eu3+ manifolds.
The emission spectrum of TbEuL, 4.6, with 487 nm excitation wavelength displayed the
expected Tb3+ transition at 545 nm and a set of peaks at 579, 592, 612, 653, 682, and 701 nm that
indicated the presence of Eu3+ emission (Figure 4.11). The latter peaks were not observed for
Tb2L, 4.8, which contained only Tb3+, and are known to originate from the 5D0 → 7F0, 5D0 →
7

F1, 5D0 → 7F2, 5D0 → 7F3, 5D0 → 7F4, and 5D0 → 7F5 transitions of Eu3+, suggesting that

excitation of the 7F0 → 5D4 transition of Tb3+ at 487 nm populates the emissive 5D0 state of Eu3+.
This phenomenon was reported for complex 4.2, although the published emission spectra only
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displayed a 580 to 620 nm range, where Tb3+ and Eu3+ emission peaks overlap.114 The major
transition in the 5D0 → 7F2 manifold appeared at 612 nm in both Eu3+- and Tb3+-centered
excitation spectra, and the transition at 616 nm, which I assigned to Eu2L, 4.7, was substantially
weaker in the spectrum of 4.6, further indicating that the source of Eu3+-based emission peaks
with 545 nm excitation was 4.6. Interestingly, the presence of the Tb3+-based transition at 545
nm and the Eu3+ based transitions suggested that the emissive process from 5D4 to 7F5 and the
energy transfer process from 5D4 to 5D0 are occurring at similar rates. Future experiments to
determine the decay rates of the emissive processes would be useful to corroborate this
observation.
Given that the 5D0 state of Eu3+ is approximately 3100 cm–1 lower in energy than the 5D4
state of Tb3+, it is reasonable to assume that energy transfer from 5D4 (Tb3+) to 5D0 (Eu3+) would
occur given a sufficiently small interatomic distance. Given the strong dependence of energy
transfer on distance, it is unlikely that intramolecular energy transfer occurs at the low
concentrations of these solutions. Therefore, energy transfer that I have observed from Tb3+ to
Eu3+ implied that the Tb3+–Eu3+ distance was within the 10 Å range required for Förster
resonance energy transfer. With the luminescence decay data for 4.7 presented in Chapter 3, this
result further supported the calculated structure of Eu2L, 4.7, and suggested that TbEuL, 4.6, has
a similar structure.
Summary and Conclusion
I have reported the synthesis of a new heterodimetallic complex 4.6 that contains Eu3+
and Tb3+ and exhibits efficient Ln–Ln energy transfer. The presence of complex 4.6 was
confirmed by ESIMS analysis and was corroborated by luminescence spectral analysis. The
energy transfer phenomenon was demonstrated by observing Eu3+-based emission with direct
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excitation of Tb3+, representing direct observation of intramolecular Ln–Ln energy transfer. A
diagram of a possible energy transfer mechanism consistent with my observations is illustrated in
Figure 4.11. The efficiency of energy transfer, though not directly measured, must be high to
observe Eu3+ emission from direct Tb3+ excitation. High efficiency energy transfer is the first
direct empirical evidence that the Ln–Ln distance is within 10 Å, suggesting that the optimized
structure of 4.7 reported in Chapter 3 represents the solution-state structure of these complexes.
Finally, these results suggest that bridged-lanthanide structures are possible for numerous
combinations of lanthanides, allowing optimization of the excitation wavelength, emission
wavelength, and lifetime properties for imaging applications.

Figure 4.12. Proposed Jablonski diagram of energy transfer from Tb3+ to Eu3+ consistent with
my observations.
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CHAPTER 5: Summary, Conclusions, and Future Directions
Introduction
Studies of multimetallic lanthanide (Ln3+) complexes relating to imaging applications
have been reported extensively to study properties relevant to contrast agents for magnetic
resonance imaging (MRI), probes for luminescence imaging, and biological interactions.34, 35, 44–
50, 72, 73, 83–87

Interestingly, the properties of some multimetallic lanthanide systems differ from

their monometallic counterparts, though few systems exhibit direct Ln3+–Ln3+ interactions.83, 113–
115

An absence of focus on Ln3+ complexes that might exhibit properties different or greater than

the sum of the Ln3+ chelates linked together prompted my approach to contribute studies clearly
focused on complexes that would likely feature Ln3+–Ln3+ interactions. The goals of my research
were to design, synthesize, and study the structural, magnetic, and luminescence properties of a
dimetallic Ln3+ complex that I hypothesized would have an unprecedented degree of Ln3+–Ln3+
interaction. These goals were aimed at elucidating new properties of Ln3+ complexes with a
particular focus on factors affecting MRI and luminescence imaging.
Ligand Design
I designed a ditopic ligand containing a 2-propanolyl moiety bridging two 1,4,7,10tetraazacyclododecane-(1,4,7-triacetate) macrocycles that I hypothesized would chelate and
bridge two lanthanide ions through an alcohol or alkoxide oxygen atom (Figure 5.1). This
hypothesis was based on previous reports of stable lanthanide complexes with cyclen-based
polyaminopolycarboxylate ligands and the preference of lanthanides for coordination that forms
5-membered rings. I further supposed that a single-atom bridge between Ln3+ ions chelated in
this ligand would result in small Ln3+–Ln3+ distances, leading to new luminescence and magnetic
properties that could be applied to problems in biological and medical imaging. Interestingly,
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after analyzing the luminescence data of the Eu3+ complex and proposing structure 5.2 to Dr.
Cisneros, he calculated the optimized structure, 5.3, that contained two additional μ-oxygen
atoms (Figure 5.1). Though 5.3 was a departure from the structure I expected, I was able to use
this complex to study Ln–Ln interactions.

Figure 5.1. (Left) Structure of ditopic ligand 5.1 also shown in Figure 2.1. (Middle)
Proposed coordination mode of ligand 5.1. (Right) Experimentally-determined coordination
mode of ligand 5.1.
Ligand Synthesis
I proposed that the synthesis of 5.1 could be achieved through hexa-tert-butyl ester
intermediate 5.6 (Scheme 5.1). However, attempts to synthesize 5.6 in one step starting from
1,3-dibromo-2-propanol (5.4) and DO3A-tris-tert-butyl ester (5.5) were unsuccessful. An
alternative method to synthesize and alkylate 5.7 yielded ambiguous results due to the possibility
that the alcohol might have been alkylated. Compound 5.16 was synthesized and successfully
converted to 5.12 but 5.1 was not generated from this route due to unsuccessful conversion of the
benzyl ether to an alcohol. However, due to the successful formation of 5.12 from 5.16, I
hypothesized that 5.12 could be synthesized by reacting the benzyl derivative of 5.4, 5.8, with
5.5. The success of this reaction indicated that the alcohol could be masked with a protecting
group without hindering the substitution of 1,3-dibromo-2-propanol derivatives. Therefore, I
prepared a series of protected 1,3-dibromo-2-propanol intermediates, 5.8 – 5.11, and screened
them in reactions with 5.5. The intermediate 5.11 successfully furnished 5.15, confirming that
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steric interference by the protecting group was not as important as I initially assumed. Side
products that interfered with purification in previous attempts were limited and the
chromatographic properties of 5.15 were unique enough that separation was achieved. As
expected, global deprotection of intermediate 5.15 generated H65.1.
Scheme 5.1. Attempted synthetic routes to synthesize protected ligands 5.6 and 5.12–5.15.

Comments on Synthetic Methods
Though several routes to synthesize 5.1 were not successful, exploring these reactions
allowed me to develop practical methods of monitoring these reactions. Specifically, I found that
monitoring these reactions with thin layer chromatography (TLC) was only useful for
determining the consumption of 1,3-dibromo-2-propanol or its derivatives, which was usually
not indicative of product formation. Also, the cyclen-containing moieties did not chromatograph
cleanly, making isolation of the components of these reactions challenging if not impossible. I
found that the most reliable method to monitor product formation in these reactions was using
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electrospray-ionization mass spectrometry. However, this method was also limited because some
components could not be detected. An example of this limitation occurred when 5-arm analogs
of 5.15, 5.19 and 5.20, were not detected and were unknowingly present through deprotection
and metallation reactions (Figure 5.2). The presence of 5.19 and 5.20 were only observed by
high performance liquid chromatography of the resulting metal complexes. The presence of these
products

highlighted

the

importance of eliminating 2arm impurities, 5.17 and 5.18,
in the synthesis of 5.5 and
highlighted the limitations of
TLC, mass spectrometry, and
NMR spectroscopy. None of
these techniques suggested the
presence

of

2-arm

contaminants in 5.5 or 5-arm
contaminants in 5.15.

Figure 5.2. Undetected contaminants in 5.5 (left) and 5.15
(right) that were not observed by TLC, MS, or NMR
characterization. Both isomers are shown but have not been
uniquely identified.

Dimetallic Eu3+-complex for Concentration-Independent pH Detection
Using ligand 5.1, I synthesized a dimetallic Eu3+ complex that I determined did not
contain water molecules coordinated to the Eu3+ ions. This result was unexpected given the
expected structure 5.2 and the fact that Eu3+ is usually 9-coordinate. However, the lack of
coordinated water suggested that the Eu3+ ions were bridged by the alcohol. Calculation of the
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optimized structure revealed two additional bridging atoms from the carboxylate arms, consistent
with the absence of coordinated water molecules (Figure 5.3).
Confident that a Eu3+–Eu3+ bridge had formed, I expected that the protonation state of the
bridging alcohol, and, therefore, the presence of a hydroxyl oscillator in the Eu3+ coordination
sphere, would be modulated by pH. Because the luminescence-decay rate of Eu3+ is dependent
on the number of hydroxyl oscillators in the coordination sphere, I hypothesized that the
luminescence-decay rate of Eu3+ in 5.21 would change with pH. Further, I expected that the
luminescence response to pH would be independent of 5.21 concentration. By measuring the
luminescence-decay rate of 0.50 mM and 1.0 mM solutions of 5.21 at different pH values, I
confirmed my hypotheses that the luminescence-decay rate of 5.21 changes with pH and that the
pH response does not depend on the concentration of 5.21. These results demonstrated a new
approach to sensing pH, wherein a property known to be independent of probe concentration
could be used to address limitations of sensing techniques: namely, the need to know the
concentration of the probe. This example also represented a new mechanism of pH-response
(Figure 5.3) that could provide a boon to biological imaging.

Figure 5.3. Structure of a dimetallic Eu3+ complex and illustration of the likely mechanism of
luminescence pH-response also reported in Chapter 3. Reprinted with permission from
Moore, J.D.; Lord, R.L; Cisneros, G.A.; Allen, M.J. J. Am. Chem. Soc. 2012, 134, 17372–
17375. Copyright 2012 American Chemical Society.
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Intramolecular Lanthanide–Lanthanide Energy Transfer in a Heterodimetallic Complex
After I determined that the tri-bridged configuration was likely representative of the
solution-state structure of 5.21 and demonstrated the utility of this complex, I sought a method to
unequivocally confirm that two lanthanide ions chelated in 5.1 could interact. I hypothesized that
a Ln–Ln interaction would be observed in the form of luminescence energy transfer between
Tb3+ and Eu3+ in adjacent sites of 5.1. This phenomenon would require that the Ln3+ ions are
within 10 Å; therefore, observation of energy transfer would also indicate that the Ln3+ ions are
likely bridged. To test these hypotheses, I synthesized and characterized complexes 5.21, 5.22,
and 5.23 (5.23 was isolated as a mixture of 5.23 and 5.21). By comparing excitation and
emission spectra of solutions of each complex, I determined that excitation of Tb3+ resulted in
emission from Eu3+. This result indicated that intramolecular Ln–Ln energy transfer occurred in
complex 5.23 from the 5D4 excited state of Tb3+ to the 5D0 excited state of Eu3+. Observation of
energy transfer confirmed that ligand 5.1 brings two Ln3+ ions within 10 Å, and likely closer.
The excitation and emission data also represent the most direct observation of Ln3+–Ln3+ energy
transfer yet reported. Further, these results expand the utility of Ln3+-based luminescence probes
by making tuning of excitation, emission, and lifetime properties to the needs of specific
applications as simple as selecting the right Ln3+–Ln3+ combination.

Figure 5.4. Dimetallic complexes reported in Chapter 4.
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Future Directions
Though I have exhausted many routes to synthesize ligand 5.1, the low yield and
impurities that hamper the synthesis of pure metal complexes should be addressed. One area that
could be explored is purification of 5.1 by HPLC. Optimization of the syntheses of 5.6 or a
derivative that could serve as an intermediate to 5.1 are likely possible and will require the
screening of many new reactions. Other derivatives of ligand 5.1, such as an analog with amide
arms, would also be interesting to determine the structural factors that are important for forming
stable Ln3+–Ln3+ bridged complexes. Finally, to unequivocally confirm the structure of these
lanthanide complexes, crystallographic data should be pursued.
Improving the emission intensity of lanthanide complexes is often achieved by installing
an organic chromophore on the chelate that will efficiently absorb and transfer photons to the
Ln3+ ion. This approach would likely prove useful to decrease the detection limit of these probes.
Low detection limits are especially important for biological applications where probe
concentration needs to be minimized to avoid toxicity and interfering with the system being
studies.
Fundamental studies on the mechanism of energy transfer would also be enlightening.
The Ln3+ emissive states are expected to be primarily f-orbital-based, and the f-orbitals are not
considered to be involved in bonding interactions; thus, I assume that the energy transfer
mechanism is purely dipolar in nature. Comparing the luminescence-decay rates of 5.23 and the
Gd3+/Tb3+ analog will likely provide insight into the mechanism of energy transfer, which would
be useful to elucidate the role, if any, of the bridging atoms. The utility of these complexes
would be greatly expanded by demonstrating that energy transfer can occur between other pairs
of Ln3+ ions and if the heterometallic complexes could be synthesized in pure form. The latter
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goal presents a formidable synthetic challenge, but control over heterodimetallic metallation
would have tremendous implications for a wide range of disciplines ranging from medicine and
biology to materials and nuclear waste applications.
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APPENDIX B
Portions of this text have been reprinted with permission from the Journal of the American
Chemical Society.
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Table B.1. Luminescence-decay rates (τ–1) of 3.1 at different pH values.

pH
4.0
4.2
4.4
4.6
4.8
5.0
5.2
5.4
5.6
5.8
6.0
6.2
6.4
6.6
6.8
7.0
7.2
7.4
7.6
7.8
8.0

3.1 (0.50 mM)
τ–1 (ms–1)
1.48
1.47
1.43
1.42
1.39
1.36
1.32
1.28
1.25
1.20
1.18
1.15
1.13
1.09
1.07
1.01
0.998
0.972
0.955
0.934
0.929

3.1 (1.0 mM)
τ–1 (ms–1)
1.49
1.48
1.45
1.42
1.39
1.35
1.33
1.28
1.25
1.20
1.17
1.14
1.12
1.09
1.07
1.02
1.01
0.978
0.950
0.948
0.930
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Figure B.2. Emission spectra of 3.1.
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Figure B.2 cont’d. Emission spectra of 3.1.
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Figure B.2 cont’d. Emission spectra of 3.1.
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pH 7.8
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Figure B.2 cont’d. Emission spectra of 3.1.
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Figure B.3. Optimized computational structure of 3.1. Labels for atoms corresponding to
distances in Table B.2.
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Table B.2. Distances between the Eu(III) ions and the first coordination sphere (in Å). Distances
between the Eu(III) ions and the bridging hydroxyl O have been bolded.
Distance 3.1 H3.1
Eu1-N1 2.98 2.82
Eu1-N2 2.96 2.84
Eu1-N3 2.91 2.75
Eu1-N4 2.84 2.84
Eu1-O1 2.34 2.31
Eu1-O2 2.38 2.40
Eu1-O3 2.40 2.45
Eu1-O4 2.42 2.44
Eu1-O5 2.49 2.48
Eu2-O3 2.36 2.91
Eu2-O4 2.52 2.56
Eu2-O5 2.40 2.34
Eu2-O6 2.33 2.25
Eu2-O7 2.33 2.44
Eu2-N5 2.93 2.95
Eu2-N6 3.26 3.07
Eu2-N7 3.14 2.97
Eu2-N8 2.73 2.71
Optimized Cartesian coordinates for 3.1.
7
7
8
8
6
1
1
6
1
1
6
1
1
6
1
1
6
1
1
6
6

-4.363586
-4.293900
-1.928546
-2.816247
-5.548558
-5.694288
-6.471270
-5.436393
-5.307331
-6.399943
-4.549963
-5.016362
-5.285507
-4.302512
-3.707899
-5.316473
-4.300763
-4.309071
-5.156685
-2.981293
-3.957250

-1.308194
1.598668
-1.756388
1.530057
-0.538554
-0.756751
-0.893400
0.971076
1.182090
1.442091
1.706595
0.763387
2.517376
-2.629946
-3.311930
-3.085768
-1.474883
-0.475883
-2.066863
-2.176286
2.906278

-0.561580
0.406659
-1.761164
-1.829745
-0.106082
0.966561
-0.623507
-0.315950
-1.388084
-0.009436
1.862079
2.194361
2.080326
0.125685
-0.499810
0.202174
-2.047442
-2.515250
-2.431489
-2.438573
-0.223214
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1 -3.148276 3.393477 0.346230
1 -4.827346 3.595288 -0.244652
6 -3.454871 2.672999 -1.659369
7 -2.257977 0.894722 2.570633
7 -2.311327 -2.016520 1.560254
8 -0.256168 1.678251 0.664366
8 0.066839 -1.034738 0.662808
6 -2.618236 -0.294009 3.387700
1 -3.714132 -0.415702 3.348935
1 -2.360156 -0.124524 4.457511
6 -1.919098 -1.577830 2.930802
1 -0.833729 -1.406994 2.933763
1 -2.134613 -2.381734 3.672748
6 -3.701652 -2.542923 1.531413
1 -4.324025 -1.881610 2.156411
1 -3.746836 -3.555716 1.998936
6 -3.284385 1.970422 2.677845
1 -2.809213 2.907236 2.346021
1 -3.573043 2.132698 3.741988
6 -0.925920 1.451939 2.963589
1 -0.215309 0.633378 3.154838
1 -1.007168 2.055854 3.888744
6 -0.362856 2.317989 1.836778
6 -1.357871 -3.012958 0.998240
1 -1.714909 -3.273225 -0.008395
1 -1.342146 -3.937174 1.622547
6 0.082941 -2.449465 0.866643
8 -2.991151 -3.093510 -3.313446
8 -0.060672 3.523345 2.031135
8 -3.678296 3.535307 -2.556073
63 -1.831590 0.098782 -0.267848
1 0.634101 -2.659108 1.809990
6 0.790175 -3.123976 -0.317744
7 2.210890 -2.684347 -0.421139
1 0.244578 -2.812404 -1.222344
1 0.727548 -4.235961 -0.243359
6 2.741694 -2.837943 -1.799176
6 3.055203 -3.395538 0.570932
1 3.843268 -2.843067 -1.735711
1 2.453570 -3.827102 -2.224911
6 2.269436 -1.758619 -2.775440
6 4.340212 -2.655841 0.965195
1 2.439896 -3.556533 1.469935
1 3.334084 -4.410521 0.200191
7 2.722466 -0.369008 -2.443824
1 1.169104 -1.744971 -2.809306

108
1 2.618365 -2.034445 -3.796342
7 4.085855 -1.337879 1.578699
1 4.963086 -2.503090 0.068193
1 4.928524 -3.324958 1.640500
6 4.195621 -0.226991 -2.628552
6 1.972700 0.604082 -3.302953
6 5.257844 -0.435084 1.567337
6 3.475805 -1.414339 2.925588
6 4.803679 0.995109 -1.936405
1 4.673266 -1.140799 -2.238637
1 4.441686 -0.177303 -3.714105
1 2.330773 1.622630 -3.078992
1 2.136619 0.390146 -4.377796
6 0.461736 0.577227 -3.015149
6 5.658289 0.058018 0.173876
1 4.998697 0.427916 2.200526
1 6.148818 -0.926250 2.032090
1 2.975530 -2.386099 3.054326
1 4.243686 -1.356763 3.728148
6 2.408492 -0.329484 3.186818
7 4.659671 0.959934 -0.451857
1 4.314218 1.910957 -2.299677
1 5.876357 1.068727 -2.229338
8 0.160872 0.402093 -1.730102
8 -0.352005 0.733157 -3.957985
1 5.812821 -0.801690 -0.500102
1 6.647054 0.568834 0.254735
8 2.304539 0.615517 2.282864
8 1.692278 -0.448416 4.232002
6 4.737342 2.336525 0.118104
63 1.817000 0.403934 0.010311
1 4.634658 2.270149 1.214348
1 5.705568 2.827184 -0.115753
6 3.585922 3.208968 -0.413241
8 2.471907 2.539654 -0.645033
8 3.769346 4.444524 -0.601403
Optimized Cartesian coordinates for H3.1.
7
7
8
8
6
1
1

-4.274561
-4.191426
-1.757151
-2.255979
-5.474065
-5.800593
-6.316861

0.008397
-1.107736
-0.087280
-2.482853
-0.327097
0.601525
-0.642690

1.404609
-1.467416
2.394832
-0.291067
0.584246
0.083295
1.238869

109
6 -5.240615 -1.426440 -0.450601
1 -4.927504 -2.353479 0.054741
1 -6.208150 -1.649034 -0.954170
6 -4.619575 -0.070656 -2.444629
1 -5.191215 0.699353 -1.900312
1 -5.311890 -0.501730 -3.201665
6 -4.432625 1.356733 2.038121
1 -3.799184 1.385683 2.935739
1 -5.477320 1.497596 2.391072
6 -3.970665 -1.023205 2.454806
1 -3.817949 -2.001852 1.968108
1 -4.794212 -1.111654 3.189470
6 -2.663561 -0.641934 3.178039
6 -3.769675 -2.369095 -2.145369
1 -3.183875 -2.126400 -3.046417
1 -4.642523 -2.971311 -2.464854
6 -2.871309 -3.192938 -1.212440
7 -2.513531 1.341910 -2.282778
7 -2.670927 2.465006 0.596130
8 -0.200944 -0.237257 -1.734755
8 -0.251120 1.566034 0.164569
6 -3.137658 2.644645 -1.883843
1 -4.212053 2.464989 -1.715770
1 -3.071254 3.371340 -2.722697
6 -2.516198 3.288006 -0.640782
1 -1.443945 3.457588 -0.809089
1 -2.978852 4.291321 -0.501137
6 -4.072077 2.514381 1.105668
1 -4.742625 2.507705 0.229661
1 -4.266250 3.471564 1.640896
6 -3.434619 0.564476 -3.172089
1 -2.826138 -0.215174 -3.658220
1 -3.818487 1.217196 -3.987319
6 -1.223892 1.563811 -3.011514
1 -0.717183 2.446159 -2.585705
1 -1.409213 1.777789 -4.081405
6 -0.210284 0.414427 -2.899925
6 -1.686819 2.852234 1.654732
1 -1.917450 2.249800 2.543832
1 -1.796954 3.928310 1.913107
6 -0.218856 2.566124 1.220146
8 -2.545276 -0.838199 4.422012
8 0.601255 0.222657 -3.840753
8 -2.757543 -4.440817 -1.367831
63 -1.925985 -0.213769 -0.001251
1 0.226302 3.482147 0.786265

110
6 0.629476 2.020863 2.376895
7 2.012964 1.581089 1.979646
1 0.092021 1.142720 2.769217
1 0.695027 2.783208 3.187235
6 2.597670 0.780110 3.103549
6 2.881411 2.756020 1.659372
1 3.694759 0.807275 3.008552
1 2.359835 1.260745 4.077786
6 2.114038 -0.669434 3.151562
6 4.243589 2.423407 1.029145
1 2.318415 3.425545 0.994431
1 3.087689 3.339405 2.586709
7 2.582028 -1.498837 1.989375
1 1.013356 -0.696834 3.164531
1 2.455257 -1.128009 4.104645
7 4.214902 1.796540 -0.325369
1 4.805909 1.751600 1.696732
1 4.821039 3.376279 0.988062
6 4.024487 -1.857892 2.135752
6 1.731359 -2.730088 1.889842
6 5.520095 1.145396 -0.639806
6 3.852907 2.797427 -1.373205
6 4.690323 -2.286068 0.827880
1 4.550046 -0.985159 2.558624
1 4.139920 -2.680449 2.875180
1 2.099527 -3.355902 1.059453
1 1.769170 -3.321672 2.824408
6 0.277906 -2.350223 1.597458
6 5.747016 -0.171737 0.108882
1 5.536439 0.958874 -1.725565
1 6.375310 1.824367 -0.420516
1 4.377474 3.761599 -1.221960
1 4.151180 2.391352 -2.354385
6 2.347300 3.041786 -1.429273
7 4.733188 -1.211097 -0.209088
1 4.144385 -3.137978 0.393007
1 5.717286 -2.650559 1.055155
8 0.158873 -1.311670 0.760908
8 -0.666155 -2.976562 2.126653
1 5.721571 0.005946 1.196382
1 6.774490 -0.532458 -0.123354
8 1.639839 1.921261 -1.354582
8 1.852631 4.199058 -1.525422
6 4.955920 -1.820810 -1.550739
63 1.944126 -0.272259 -0.340350
1 5.179161 -1.022595 -2.278327

111
1
6
8
8
1

5.814280
3.693863
2.562617
3.791550
0.390473

-2.521947
-2.552993
-2.069308
-3.510287
1.847134

-1.550366
-2.039913
-1.553873
-2.851924
-0.608756
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I synthesized and characterized new homo- and heterodimetallic Eu3+- and Tb3+containing complexes. Solution-phase luminescence measurements and density functional theory
(DFT)-optimized structures indicated that all complexes were nearly isostructural and contained
a dimetallic lanthanide core bridged by three oxygen atoms that are covalently bound to the
ligand backbone. The homodimetallic Eu3+ complex behaved as a concentration-independent pH
sensor that correlates the luminescence-decay rate of the complex to pH. The probable
mechanism of pH sensing was attributed to the modulation of a hydroxyl oscillator in the Eu3+
coordination sphere, which was a previously unreported method to sense pH. The
heterodimetallic Tb3+/Eu3+ complex displayed energy transfer from Tb3+ to Eu3+ that is
unprecedentedly efficient. The observed energy transfer confirmed that the Tb3+–Eu3+ distance in
the heterodimetallic complex is within 10 Å and demonstrated a unique interaction between
lanthanide ions.
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